NABI wird sauber rebounden - 500 Beiträge pro Seite (Seite 3)

[nkelchen]

[posting]19.963.744 von loseit am 30.01.06 19:48:28[/posting]

Ja, Sie lebt noch, sie lebt nochh, sie lebt noch....


nk
*mein Orakel sieht 2stellig*

[B2L]

good news ......

-------------------------------------

http://www.finanznachrichten.de/nachrichten-2006-02/artikel-…


-------------------------------------


02.02.2006 01:20
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for Civacir to Prevent Hepatitis C Re-infection in Liver Transplants

ROCKVILLE, Md., Feb. 1 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nachrichten) today announced important regulatory and clinical advancements for its product candidate Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing Hepatitis C virus re-infection in liver transplants. Civacir has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Under the FDA Modernization Act of 1997, Fast Track regulations facilitate the development of products that treat serious diseases where an unmet medical need exists. Fast Track regulations are also designed to expedite the review process for designated products, including the potential for companies to ask for priority review.

The company also announced today that recent discussions with regulators in the U.S. and EU have been very productive with respect to advancing the development program for Civacir. Based on this important input, Nabi Biopharmaceuticals believes that a proof-of-concept Phase II trial, followed by a single pivotal Phase III study, would be adequate for licensure in the U.S. and Europe, assuming that prospectively defined endpoints are met. The Phase II proof-of-concept study will be designed to add to the knowledge of how Civacir works and the levels of antibodies needed to protect the transplanted liver from re-infection with the Hepatitis C virus.

In addition, Nabi Biopharmaceuticals announced today that consistent with its overall approach to product development, it is establishing an outside scientific and clinical advisory panel to work with the company on the Civacir development program. The company believes that the input and guidance it receives from the panel, combined with input from regulatory bodies in the U.S. and Europe, will be valuable in advancing the regulatory, clinical and commercial development path for Civacir and lead to the design of an optimal Phase III pivotal trial for this first-of-its-kind product.

The Fast Track Designation is the latest in a number of regulatory milestones achieved with Civacir by Nabi Biopharmaceuticals. In June 2005, the company announced that it had gained Orphan Medicinal Product (OMP) designation for Civacir in Europe. If a product with OMP designation is the first to receive marketing authorization in Europe for its designated indication, the product will be entitled to 10-year market exclusivity, thereby preventing a similar drug from receiving authorization for the same indication during this period. OMP designation in the EU was an important milestone for Nabi Biopharmaceuticals, as it represents further validation for the need for new treatment approaches in the care of HCV-positive liver transplant patients. Civacir received orphan drug status in the U.S. in 2002. Among other benefits of orphan drug designation, Civacir will be entitled to seven years of market exclusivity in the U.S., post-launch, thereby preventing a similar drug from receiving authorization for the same indication during this period.

About Civacir

Designed to be the first therapy approved specifically for the prevention of recurrence of Hepatitis C-related liver disease in HCV-positive liver transplant recipients, or in patients who receive a HCV-positive liver, Civacir has the potential to fill a critical void in treatment options for this vulnerable patient population. Most notably, market research completed by the company in 2005 supports growing physician awareness and support for this potential new treatment alternative for HCV. This increased awareness is due, in part, to the following factors:

* Currently, there are no products that can be dosed safely at the time of transplant or immediately after transplant in hepatitis C-positive liver transplant recipients; and as a result, transplanted livers universally become re-infected; * Current products and products under development for maintenance tend to convey a poor risk-benefit ratio in liver transplant recipients; and * Due to the variations in strains of the Hepatitis C virus, it is well recognized that a polyclonal antibody approach is needed; a monoclonal antibody is unlikely to be effective.

HCV is the most common chronic blood-borne infection in the U.S. and a leading cause of end-stage liver disease resulting in liver transplantation. Interferon and ribavirin, currently available treatments, have demonstrated limited efficacy in chronically infected HCV patients. Furthermore, these therapies cannot be used to protect liver transplant patients from HCV re- infection after surgery and are considered too toxic for immune-suppressed liver transplant patients. As a result, among chronic HCV patients who undergo liver transplantation, HCV recurrence in the transplanted liver is nearly universal(1). In addition, associated severe side effects often lead to dose reductions and discontinuation of treatment.

Henrik S. Rasmussen, M.D., Ph.D., senior vice president clinical, medical and regulatory affairs, Nabi Biopharmaceuticals, stated, "The Fast Track Designation provided by the FDA not only acknowledges Civacir as a viable potential treatment option for HCV patients, but it also recognizes that current therapies are inadequate. Nabi Biopharmaceuticals has engaged in extensive and productive discussions with the FDA and the European Medicines Agency regarding the optimal development path for Civacir. The guidance we have received from these organizations and other third parties will be critical factors in the future development of Civacir. Based on input received so far, we plan to initiate a larger dose-ranging proof-of-concept Phase II study later this year."

Next Steps: Civacir Development Program (Phase II Proof-of-Concept Study)

Nabi Biopharmaceuticals plans to initiate a Phase II proof-of-concept study for Civacir in the second half of 2006. This timing is aligned with our goal to have the clinical lot of Civacir manufactured by October 2006, a critical and required step before trial initiation. It is also important to note that Nabi Biopharmaceuticals has developed important technical know-how through a unique and safe production process for Civacir that allows for the separation of high-quality antibodies from patients infected with Hepatitis C.

We believe this timing and product development approach will support our goals of completing enrollment within twelve months, and, subsequently, having data available in the second half of 2008.

The trial will be designed as a double-blinded, placebo-controlled study in approximately 100 HCV-positive patients, post-liver transplant (3 active dose levels, 100, 200 and 400mg/kg, 25 patients per group). The endpoints of the trial are: progression of liver fibrosis; liver enzyme levels; and safety and tolerance. Nabi Biopharmaceuticals plans to conduct the trial in the U.S. and EU.

Thomas H. McLain, chairman, chief executive officer and president, Nabi Biopharmaceuticals, stated, "Civacir is an important and strategic part of Nabi Biopharmaceuticals` product portfolio and our global hepatitis franchise. Civacir leverages assets and competencies within Nabi Biopharmaceuticals today, including our expertise in plasma collection, manufacturing, clinical and regulatory, and sales and marketing, and it builds upon our commercial success with Nabi-HB(R) [Hepatitis B Immune Globulin (Human)] the current gold standard for Hepatitis B. Combined, Civacir and our Nabi-HB product, currently marketed for the prevention of HBV infections following acute exposure, could represent better medical care for patients and a reduction in healthcare dollars spent on additional transplants. Nabi Biopharmaceuticals remains committed to advancing this clinically and commercially important global franchise."

About Liver Transplants and Hepatitis C

There are approximately 6,000 liver transplants conducted yearly in U.S. and 4,000 in the EU, the majority of which are due to Hepatitis C. Furthermore, the proportion of transplants due to Hepatitis C is expected to increase as other causes of end-stage liver disease decrease (i.e., Hepatitis B).

Hepatitis C is the most common cause of end-stage liver disease in the developed world. Most transplant patients, because of their immunocompromised status, suffer immediate re-infection of the liver, which in many cases will progress to liver cirrhosis and can eventually result in death or the need for a re-transplantation. The U.S. Centers for Disease Control and Prevention (CDC) estimates that approximately three million individuals in the U.S. are chronically infected with HCV, and the World Health Organization (WHO) estimates that 170 million individuals worldwide are infected with HCV. The virus can be transmitted through blood transfusion, organ transplants, intravenous drug use, kidney dialysis and sexual contact.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are focusing on developing products addressing commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and pre-clinical development. The company also filed Marketing Authorization Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver transplant patients; and for PhosLo, which is already marketed in the United States. The company`s products in development include NicVAX(TM) (Nicotine Conjugate Vaccine), a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com/.

This press release contains forward-looking statements that reflect the company`s current expectations regarding future events. Any such forward- looking statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may differ significantly from those in the forward-looking statements as a result of any number of factors, including, but not limited to risks relating to the company`s ability to: advance the development of products currently in the pipeline or in clinical trials; complete the assessment of the StaphVAX Phase III clinical trials during the first half of 2006; maintain the human and financial resources to commercialize current products and bring to market products in development; obtain regulatory approval for its products in the U.S. or other markets; successfully develop manufacture and market its products; utilize the full capacity of its manufacturing facility; realize the value of its acquisition of PhosLo; realize sales from Nabi-HB due to patient treatment protocols and the number of liver transplants performed in HBV-positive patients; realize the value from its vaccine manufacturing facility; realize future sales growth for its biopharmaceutical products; prevail in patent litigation; raise additional capital on acceptable terms; re-pay its outstanding convertible senior notes when due; and the company`s dependence upon: third parties to manufacture its products and a small number of customers. Many of these factors are more fully discussed, as are other factors, in the company`s Annual Report on Form 10-K for the fiscal year ended December 25, 2004 filed with the Securities and Exchange Commission.


(1) U.S. Department of Health and Human Services. Management of Hepatitis C: 2002. NIH Consensus State Sci Statements. National Institutes of Health, 2002 Jun 10-12; 19 (3) 1-46

[B2L]

Nabi Pharma Hepatitis Drug Gets FDA Fast Track Status




02-01-06 08:53 PM EST
ROCKVILLE, Md. -(Dow Jones)- Nabi Biopharmaceuticals (NABI) on Wednesday said its hepatitis C drug, Civacir, received a fast track designation by the Food and Drug Administration.

The news sent Nabi`s stock up more than 16% to $4.44 in late-trading activity.

In a press release, Nabi also said that recent discussions with U.S. and European regulators have been very productive to advane the development program for Civacir.

As a result, Nabi believes that a proof-of-concept Phase II trial, followed by a single pivotal Phase III study, would be adequate for licensure in the U.S. and Europe, assuming that prospectively defined endpoints are met.

The Phase II proof-of-concept study will be designed to add to the knowledge of how Civacir works and the levels of antibodies needed to protect the transplanted liver from re-infection with the Hepatitis C virus.

-Freddy Sebastian; Dow Jones Newswires; 201-938-5400

[Freestyler2001]

ungefähr so ging es mir gerade, wenn sich das halten und der tiefe Kaufkurs da mal nicht lohnt, das ist ein heißer Kandidat für den zweistelligen Bereich

GO NABI

[B2L]

[posting]20.005.953 von Freestyler2001 am 02.02.06 09:51:53[/posting]ganz deiner Meinung

[nkelchen]

[posting]20.006.082 von B2L am 02.02.06 09:59:34[/posting]

ZEN, wo biste?!


nk
*Geduld ist eine Tugend*

[Isabartels]

Tja Zen!

[weinicht]

Naja..die wird ja schon wieder mächtig gebremst...hätte nen Verkaufsorder in den Markt legen sollen.

[nkelchen]

[posting]20.012.428 von weinicht am 02.02.06 16:01:24[/posting]

Die wollen doch nicht etwa noch das Gap schliessen!!

Unter 3,90 haue ich eine Trading Posi rein, wenn dem so
sein sollte...

nk
*diese Lackaffen...*

[Freestyler2001]

da stinkt was gewaltig, nach wie vor verdienen Shorties an dem Wert, wenn der Druck weg ist...und bei der Nachrichtenlage geht das nicht mehr lange so, geht Nabi ab...unter 10€ verkauf ich keine Aktie.

[zenman]

mensch nk

NABI is einfach nur traurich
ich hätts euch echt gegönnt
wär selber vorhin fast zu 4,08 wieder rein

[B2L]

ist ja wirklich ein Sch..ssteil .....

[nkelchen]

[posting]20.014.722 von zenman am 02.02.06 18:13:05[/posting]

ich bin total entspannt!
Rebound Depot +20%
wat will ich denn mehr?!

Heute gibt es ein Schlachtfest Freunde!!!!!!
Kürzel RHEO

OccuLogix Inc. (RHEO:
occulogix inc com
News, chart, profile, more
Last: 12.75+0.35+2.82%

7:56am 02/03/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:

Ameritrade. Get up to $100 cash.RHEO12.75, +0.35, +2.8%) reported negative results of a phase III trial of MIRA-1, a proposed treatment for the dry form of age-related macular degeneration. The Toronto-based biotechnology company said the MIRA-1 trial missed its primary endpoint, failing to demonstrate a statistically significant difference between the treated group and the placebo control group. OccuLogix is in the process of evaluating the implications of the data on its application for marketing approval from the Food and Drug Administration. The stock closed Thursday at $12.75, up 2.8%.


nk

[nkelchen]

[posting]20.028.749 von nkelchen am 03.02.06 14:16:57[/posting]

so ein Zufall -
und der Mob kaufte weiter...




nk

[Isabartels]

Werde mir heute mal ein paar Siri kaufen (904591)

[nkelchen]

[posting]20.030.401 von Isabartels am 03.02.06 15:34:13[/posting]

war eben von 3,55 bis 4,22 dabei
(nur sehr kleine Posi)

nk
*die sollten in den nächsten Tagen noch um die 3€
zu kriegen sein*

[weinicht]

Können wir mal beim Thema bleiben??

[zenman]

genau
thema is scheiss-NABI

[Isabartels]

????
Wo warst Du drin????

[B2L]

[nkelchen]

[posting]20.064.771 von B2L am 06.02.06 15:54:46[/posting]

Nabi Biopharmaceuticals Announces Positive Phase I Results From Its S. epidermidis PS-1 and S. aureus Type 336 Vaccine Clinical Trials
-- Results Show Company`s Proprietary Conjugate Technology is Highly Effective in Stimulating Antibody Response; Moving into Phase II Testing --
2/7/2006 8:30:32 AM










Feb 07, 2006 /PRNewswire-FirstCall via COMTEX/ -- Nabi Biopharmaceuticals (NABI) today provided an update on the development of its Gram- positive infections program, which includes several product candidates for the prevention and treatment of S. aureus, S. epidermidis and enterococcal infections. Together these bacteria account for two-thirds of healthcare- associated infections reported annually.







MARKETWATCH TOP NEWS
Stock futures ease as Toll Brothers warns; GM ahead
GM chief to speak; dividend reportedly will be cut
BP profit rises 22% on oil prices, refining services
Portugal Telecom soars on Sonae`s $12.8 billion offer
Disney shares gain as earnings beat expectations


TRACK THESE TOPICS
Alerts
Company: Nabi Biopharmaceuticals
Create

Get Breaking News sent directly to your inbox




Create An Alert

Nabi Biopharmaceuticals announced positive data from Phase I studies of the company`s S. epidermidis PS-1 vaccine and its S. aureus Type 336 vaccine. Both Phase I studies evaluated the safety and immune response of these vaccines in healthy volunteers. The data support that escalating doses of the vaccines were well tolerated and resulted in significant dose-related increases in levels of antibodies against S. epidermidis PS-1 and S. aureus Type 336. The results of these studies also support the company`s conjugation technology in stimulating antibody responses. High antibody titers against specific targets are critical in conferring protection to patients against these infections.

Thomas H. McLain, chairman, chief executive officer and president, Nabi Biopharmaceuticals, stated, "Clinically, Nabi Biopharmaceuticals is focused on addressing a large, unmet medical need. Collectively, S. epidermidis and S. aureus represent approximately 80 percent of all Gram-positive hospital- acquired bacterial infections. Commercially, we are focused on developing products that address a large, underserved market. It is estimated that by 2008 the market for new hospital anti-bacterial products will reach $10.1 billion. Our product, growth and business strategies remain aligned with global trends and policies that have defined the critical need for effective and cost-efficient treatments and preventative solutions. In this way, Nabi Biopharmaceuticals is uniquely and strategically positioned to capitalize on its technology and expertise to develop a portfolio of vaccines and antibody products via our own resources and, when appropriate, with strategic partners."

These results and the direction of the company`s Gram-positive program are important for several reasons, including the clinical and commercial potential of vaccines to prevent S. epidermidis and S. aureus infections, as well as antibody and other innovative approaches that Nabi Biopharmaceuticals plans to develop products to treat and prevent these infections:

The Clinical and Economic Challenges

S. epidermidis and S. aureus are Prevalent and Resistant to Antibiotics. Current preventative and treatment approaches fall short of adequately addressing S. epidermidis and S. aureus infections, which are increasingly becoming resistant to antibiotics. These bacteria often live transiently or permanently in the nasal passages or on the skin of humans; and can spread to the blood through breaks in the nasal membranes or skin.

S. aureus and S. epidermidis infections are prevalent in hospitals and account for the majority of bloodstream infections. There are approximately 2.6 to 2.8 million hospital-associated infections reported annually. The mean cost is estimated at $13,973 per infection or a range of $36.3 - $39.1 billion annually. The estimated overall mortality rate associated with hospital- associated (nosocomial) bloodstream infections and pneumonia are 23.8 percent to 50 percent and 14.8 percent to 71 percent, respectively.

It is estimated that healthcare-associated treatment costs associated with S. epidermidis infections total almost $600 million each year. To add to the economic burden, methicillin-resistant S. epidermidis (MRSE) rates have reached approximately 80 percent, and over 50 percent of S. epidermidis infections are also resistant to other currently administered anti-microbials. Associated S. epidermidis mortality rates total over 20 percent.

Type 336 accounts for approximately 20 percent of S. aureus infections that do not form a polysaccharide capsule in the human bloodstream. In addition, another 30 percent of S. aureus bacteria are partially encapsulated and Type 336 may also have benefit in preventing and treating infections caused by those bacteria. Since its initial identification in the 1960s, hospital-associated methicillin-resistant S. aureus (MRSA) rates have climbed to 57 percent in the ICU and to over 40 percent in non-ICU in-patient settings by 2002. It is estimated that over 30 percent of the adult population at any given time are colonized with S. aureus.

A Multi-faceted Solution

Both vaccines are the first-of-their kind in development to prevent S. epidermidis and S. aureus Type 336 in patients, including those undergoing certain types of invasive surgery, patients in intensive care or shock-trauma units, patients receiving cancer chemotherapy or other immune suppressive treatments, dialysis patients and patients in long-term care facilities.

The PS-1 antigen is found on approximately 60 to 70 percent of all S. epidermidis strains. Immunization with PS-1 results in the production of antibodies that attack a cell wall structure of the bacteria. The mechanism of action of the Type 336 vaccine is independent of the polysaccharide capsule targeted by the company`s S. aureus Types 5 and 8 vaccine approach, in that it attacks a structure in the cell wall of the bacteria, not the polysaccharide capsule outside the cell wall. Our research indicates that what we target in S. aureus Type 336 is cross-reactive to S. epidermidis. As an example, data already support that Type 336 antibodies are cross reactive with the majority of S. epidermidis bacteria. The results announced today clearly support moving these programs into Phase II clinical testing.

Raafat E.F. Fahim, Ph.D., senior vice president research, technical and production operations, Nabi Biopharmaceuticals, stated, "Nabi Biopharmaceuticals` R&D pipeline is deep as we plan to develop several unique approaches to Gram-positive infections. In addition to the capsular and non- capsular approaches to S. aureus and the proprietary targets to S. epidermidis, we are also developing novel vaccines and antibody products to enterococci, community-acquired MRSA, as well as anti-infective approaches to nasal colonization, skin and soft tissue Staph infections."

Dr. Fahim continued, "We are also fortunate to have the manufacturing capabilities to produce these vaccines and antibody products in our own Boca Raton facilities."

Upcoming Milestones

During 2006, the company will further study these vaccine candidates as stimulating agents to produce antibody products active against these dangerous bacteria. Antibodies can be used for prevention in patients at immediate risk for infection and may act synergistically with antibiotics in the treatment of active infections.

Based on the Phase I clinical trial results announced today and the potential to develop these vaccines and antibodies in a variety of ways, Nabi Biopharmaceuticals will advance its S. epidermidis PS-1 and S. aureus Type 336 programs into a Phase II clinical trial designed as a "proof-of-concept" study. The company expects to initiate this clinical trial in the first half of 2007 and it will evaluate the benefit of a multi-valent product in reducing or treating infection in patient populations at-risk for infection. The company will work with its Gram-positive infections advisory panel to both define the study population and advise whether the vaccine or antibody product should first advance into late-stage clinical study. Based on the outcome of the StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate Vaccine] assessment, this trial may or may not involve combination with capsular polysaccharide Types 5 and 8. Nabi Biopharmaceuticals anticipates that the next trial will be conducted in both U.S. and EU sites.

About the S. epidermidis PS-I Study

The S. epidermidis PS-I Phase I study was a double-blinded, placebo- controlled study evaluating safety and antibody responses of the vaccine in 36 patients at three different dosage levels. Within each of these three dose groups there were 12 patients, nine receiving the S. epidermidis vaccine and three receiving placebo. The doses were administered in an escalating manner.

About the Type 336 Study

The Type 336 Phase I study was a double-blinded, placebo-controlled study evaluating safety and antibody responses of the vaccine in 48 patients at four different dosage levels. Within each of these four dose groups there were 12 patients, nine receiving the Type 336 vaccine and three receiving placebo. The doses were administered in an escalating manner.

Henrik S. Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, Nabi Biopharmaceuticals, stated, "A growing number of patients, such as patients with indwelling catheters, patients in intensive care units, patients receiving cancer chemotherapy, surgical patients receiving implantation of various devices, dialysis patients and premature babies, develop staphylococcus bacterial infections, either S. aureus or S. epidermidis. To add to this problem, these bacteria are becoming increasingly resistant to a number of different antibiotics. As a result, S. aureus and S. epidermidis infections often lead to severe illness and death. Consequently, new and more effective solutions, such as vaccines and antibodies, are urgently needed."

Mr. McLain concluded, "Our Gram-positive infections program is robust, and aligned with the company`s business strategy to develop clinically relevant, efficacious and cost-effective products in areas of significant unmet medical need. We are pleased with today`s S. aureus Type 336 and S. epidermidis PS-1 results, as they support our strategic approach in advancing our Gram-positive infections program. This approach would be combined with our S. aureus Types 5 and 8 program to develop a next generation product, if the outcome of our ongoing assessment is positive."

The company also announced that progress continues in its investigation of results from a recent Phase III study of its S. aureus Types 5 and 8 vaccine candidate, StaphVAX. The company confirmed that it expects to review the results of the investigation with its outside advisory panel and define plans for this element of its Gram-positive infections program in the first half of 2006.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are focusing on developing products addressing commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and pre-clinical development. The company also filed Marketing Authorization Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver transplant patients; and for PhosLo, which is already marketed in the United States. The company`s products in development include NicVAX(TM) (Nicotine Conjugate Vaccine), a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com .

This press release contains forward-looking statements that reflect the company`s current expectations regarding future events. Any such forward- looking statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may differ significantly from those in the forward-looking statements as a result of any number of factors, including, but not limited to risks relating to the company`s ability to: advance the development of products currently in the pipeline or in clinical trials; complete the assessment of the StaphVAX Phase III clinical trials during the first half of 2006; maintain the human and financial resources to commercialize current products and bring to market products in development; obtain regulatory approval for its products in the U.S. or other markets; successfully develop manufacture and market its products; utilize the full capacity of its manufacturing facility; realize the value of its acquisition of PhosLo; realize sales from Nabi-HB due to patient treatment protocols and the number of liver transplants performed in HBV-positive patients; realize the value from its vaccine manufacturing facility; realize future sales growth for its biopharmaceutical products; prevail in patent litigation; raise additional capital on acceptable terms; re-pay its outstanding convertible senior notes when due; and the company`s dependence upon: third parties to manufacture its products and a small number of customers. Many of these factors are more fully discussed, as are other factors, in the company`s Annual Report on Form 10-K for the fiscal year ended December 25, 2004 filed with the Securities and Exchange Commission.

SOURCE Nabi Biopharmaceuticals

Thomas E. Rathjen, Vice President, Investor Relations, Nabi Biopharmaceuticals,
[phone]


http://www.prnewswire.com


Copyright (C) 2006 PR Newswire. All rights reserved. ********************************************************************** As of Friday, 02-03-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 07-13-2005 for NABI @ $14.36. (C) 2006 Comtex News Network, Inc. All rights reserved.


mich machen die nicht mürbe, die Pillendreher..
nk

[B2L]

[posting]20.081.186 von nkelchen am 07.02.06 14:39:13[/posting]mich machen die nicht mürbe ....


ich kenne das ..... bei den US Klitschen machen die shorties einen ziemlich mürbe ....

[B2L]

[posting]20.082.096 von B2L am 07.02.06 15:27:32[/posting]zack ........ und gleich wieder unter 4 USD.....


die shorties haben das Teil noch fest in der Hand

[zenman]

jaja
ich weiss
hier tut sich auch was
aber
ihr solltet euch GENTA auch nich entgehn lassen

zen

[Isabartels]

Hättet Ihr mal auf meinen Tip bei #1015 gehört. Gabs zu 5,3$. Jetzt über 6!!

[B2L]

10.02.2006 17:38
Nabi Biopharmaceuticals to Present at the BIO CEO and Investor Conference 2006

BOCA RATON, Fla., Feb. 10 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nachrichten) announced today that Thomas H. McLain, chairman, chief executive officer and president, and Henrik Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, will be presenting at the BIO CEO and Investor Conference 2006 on Tuesday, February 14, 2006, at 10:30 am ET at the Waldorf Astoria Hotel, Louis XVI Center/West, 301 Park Avenue, New York, New York. Mr. McLain will present a company overview, and Dr. Rasmussen will speak about NicVAX(TM) (Nicotine Conjugate Vaccine), the company`s pipeline product for nicotine cessation.

The presentation will be webcast live at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NAB…

The webcast will be available through March 14, 2006. About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)]. Nabi Biopharmaceuticals is focused on developing products which address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology) and nicotine addiction. Click here for a complete list of our pipeline products. The company traces its history to 1967 and is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com/ .

First Call Analyst:
FCMN Contact: [e-mail]
Audio:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NAB…

[nkelchen]

[posting]20.145.485 von B2L am 10.02.06 23:04:50[/posting]

Der Event scheint gut gelaufen zu sein..

Es ist halt, wie es meist ist,
seit einer Woche kein Beitrag mehr im Thread
und der Kurs schleicht zu neuen 2006er Höhen!


nk
*alles eine Frage der Geduld*

[nkelchen]

nk

[Obdukatze]

Hallo,
endlich wieder mal jemand im Tread.
Still und leise geht der Kurs nach oben (und keiner postet)
Interesant wird der Kurs aber erst, wenn Substanz kommt.
Gruß
Obdu

[nkelchen]

[posting]20.257.579 von Obdukatze am 17.02.06 15:39:10[/posting]
Hallo Du Katze!

break 4,20 gelungen, das kann heute noch richtig fett grün werden!

Vielleicht haben die shortguys ja fertig?!

Gruss
nk

[nkelchen]

[posting]20.258.371 von nkelchen am 17.02.06 16:05:48[/posting]

Neues after desaster High bei 4,36

Umsatz 700k in 2h
Das ist heute der Start zum Rebound!!!

nk
*feel the spirit*

[Obdukatze]

[posting]20.260.052 von nkelchen am 17.02.06 17:18:29[/posting] Es wird schon werden!

[Obdukatze]

richtig nkelchen .
02/17/06 4.19 4.36 4.10 4.28 +0.12 905853 +2.88%
02/16/06 4.10 4.18 4.09 4.16 +0.07 1391200 +1.71%
02/15/06 4.01 4.14 4.00 4.09 +0.05 1518000 +1.24%
02/14/06 3.97 4.04 3.91 4.04 +0.07 1237700 +1.76%
02/13/06 3.92 3.97 3.87 3.97 +0.05 1145000 +1.28%

[Obdukatze]

hier etwas übersetztes.

BOCA RATON, FLA., FEB. 10 /PRNEWSWIRE-FIRSTCALL /-- NABI BIOPHARMACEUTICALS VERKÜNDETE HEUTE DIESER THOMAS H. MCLAIN, VORSITZENDE, HAUPT LEITENDER OFFIZIER UND PRÄSIDENT, UND HENRIK RASMUSSEN, DOKTOR DER MEDIZIN, PH.D., ÄLTERER VIZE PRÄSIDENT, KLINISCHE, MEDIZINISCHE UND VORSCHRIFTSMÄßIGE ANGELEGENHEITEN, WIRD BEI PRÄSENTIEREN DAS BIO CEO UND INVESTOR KONFERENZ 2006 AM DIENSTAG, DER 14. FEBRUAR 2006, UM 10:30 IST ET BEIM WALDORF ASTORIA HOTEL, LOUIS XVI CENTER/WEST, 301 PARK-AVENUE, NEW YORK, NEW YORK,. HERR MCLAIN WIRD EINEN GESELLSCHAFT-ÜBERBLICK PRÄSENTIEREN, UND DR. RASMUSSEN WIRD VON NICVAX(TM SPRECHEN) (NIKOTIN KONJUGIERT IMPFSTOFF), DAS PIPELINE-PRODUKT DER GESELLSCHAFT FÜR NIKOTIN-EINSTELLUNG.


DIE WEBCAST WERDEN DURCH DEN 14. MÄRZ 2006 VERFÜGBAR SEIN. ÜBER NABI BIOPHARMACEUTICALS NABI BIOPHARMACEUTICALS HEBELKRÄFTE SEINE ERFAHRUNG UND WISSEN IM ANTREIBEN DES IMMUNEN SYSTEMS, UM ZU ENTWICKELN UND PRODUKTE ZU VERKAUFEN, DIE ERNSTE MEDIZINISCHE ZUSTÄNDE BEKÄMPFEN.

DIE GESELLSCHAFT HAT DREI PRODUKTE AUF DEM MARKT HEUTE: PHOSLO(R) (KALZIUM-AZETAT), NABI-HB(R) [LEBERENTZÜNDUNG B IMMUNES GLOBULIN (MENSCH)], UND ALOPRIM(TM) [ALLOPURINOL NATRIUM (FÜR EINSPRITZUNG)]. NABI BIOPHARMACEUTICALS WIRD AUF NEU ENTSTEHENDEN PRODUKTEN KONZENTRIERT, DIE UNMET MEDIZINISCHE BEDÜRFNISSE UND ANGEBOT KOMMERZIELLE GELEGENHEITEN IN UNSEREN KERN-UNTERNEHMEN-GEBIETEN ADRESSIEREN,: GRAMM-BESTIMMTE BAKTERIELLE INFEKTIONEN, LEBERENTZÜNDUNG, NIERE-KRANKHEIT (NEPHROLOGY) UND NIKOTIN-SUCHT. KLICKEN SIE HIER FÜR EINE VOLLSTÄNDIGE LISTE UNSERER PIPELINE-PRODUKTE. DIE GESELLSCHAFT VERFOLGT SEINE GESCHICHTE ZU 1967 UND IST HEADQUARTERED IN BOCA RATON, FLORIDA. FÜR ZUSÄTZLICHE INFORMATIONEN ÜBER NABI

Obdu

[cyberhai]

Die Quartalszahlen sind da:

http://biz.yahoo.com/prnews/060223/flth020.html?.v=39

Gruß Cyberhai

[B2L]

Sche..szahlen ...........

[Freestyler2001]

ein Einbruch war zwar zu erwarten, aber die Zahlen sind wirklich nicht die besten,was mich vorallem stört ist der Satz : "The correction of this error in the fourth quarter reduces PhosLo sales by $3.9 million. This error was not material to any of the company`s previously reported quarterly results " solche Fehler sollten nicht unterlaufen. Naja damit kriegen die Shorties neue Nahrung, das könnte noch heiter werden, ich hoffe aber, dass sich der Kurs stabilisiert.MfG Free

[Obdukatze]

Zahlen ? alles gut und schön!
Beim Vergleich zum Höchststand ist der Kurs immer noch human bewertet.
06.2005 high bei 13 Euro, das war ein lockerer Kursbschlag von 70%.
Umsatzverlust zu 2004 ca 40 %.
Also locker bleiben
Gruß
Obdu

[Obdukatze]

Kurs scheint sich wieder zu erholen.
Momentan 3,84
02/24/06 3.90 3.91 3.76 3.84 -0.34 1567169
http://www.usa-aktienprofi.de/nasdaq.htm

[Freestyler2001]

Guten Morgen Nabi-aner, neue Woche neues Glück, mit einer hoffentlich baldigen Kurserholung.

[nort.]

Lesezeichen

[nort.]

Schöne Zusammenfassung für 2006

2006 Milestone plan
by: senor_gato_malo
Long-Term Sentiment: Strong Buy 02/27/06 08:04 pm
Msg: 36693 of 36714

I am reposting this for anyone that is still undecided in buying this stock. You need to realize the huge potential up-side to this company. This is not pumping - just facts.


http://biz.yahoo.com/prnews/060223/flth020.html?.v=39

2006 Milestones

* Issue a report summarizing the conclusions reached with the outside panel of experts on the analysis of the StaphVAX clinical program. This report is expected during the first half of 2006.

* Initiate the NicVAX Phase II proof-of-concept study, scheduled to commence during the second quarter of 2006, to assess safety, efficacy and optimal dose regimen. This trial is expected to generate statistical data sufficient for a decision whether to proceed to a pivotal Phase III study.

* Begin the Civacir Phase II proof-of-concept study scheduled to commence during the second half of 2006, to assess safety, efficacy and optimal dose regimen. This trial is expected to generate statistical data sufficient for a decision whether to proceed to a pivotal Phase III study.

* Advance the preparations for a Phase II proof-of-concept study for a multi-valent vaccine or antibody product targeting S. epidermidis infections scheduled to commence during the first half of 2007. The benefit of a multi- valent product in reducing or treating infection in high-risk patient populations will be evaluated. Based upon the outcome of the StaphVAX assessment, this trial may incorporate antigens to the capsular polysaccharide to S. aureus Types 5 and 8.

* Receive EU approval of PhosLo, anticipated during the first half of 2006.

* Complete the PhosLo CARE2 and EPICK studies in the second half of 2006.

* Based on expected EPICK data, submit license applications in the U.S. and Europe for an indication for the use of PhosLo to control hyperphosphatemia in chronic kidney disease patients in the second half of 2006.

* Receive EU approval of Nabi-HB® Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade name of HEBIG(TM).

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=…

[nkelchen]

[posting]20.426.207 von nort. am 28.02.06 16:58:08[/posting]
http://finance.yahoo.com/q/sa?s=nabi

nk

[nort.]

perfekt

[nort.]

$7 TRADES! Click Here Click Here

Press Release Source: Nabi Biopharmaceuticals

Nabi Biopharmaceuticals to Present at the Lehman Brothers Ninth Annual Global Healthcare Conference
Friday March 3, 8:39 am ET

BOCA RATON, Fla., March 3 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI - News) announced today that Thomas H. McLain, chairman, chief executive officer and president, will be presenting at the Lehman Brothers Ninth Annual Global Healthcare Conference on March 9, 2006, at 8:30 am ET at the Loews Miami Beach Hotel, Poinciana 4 Room, 1601 Collins Avenue, Miami Beach, Florida. Mr. McLain will present a company overview, and Henrik Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, will speak about Civacir® [Hepatitis C Immune Globulin (Human)], the company`s investigational human polyclonal antibody product that contains antibodies to hepatitis C virus (HCV). Civacir is being developed to prevent hepatitis C disease in HCV-positive liver transplant patients and is being evaluated for the treatment of chronic hepatitis C virus infections. Civacir has received Orphan Drug Designation from the U.S. Food and Drug Administration.

The presentation will be webcast live at:
http://customer.talkpoint.com/LEHM002/030806a_cs/default.asp…

The webcast presentation will be available through April 3, 2006.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology) and nicotine addiction. For a complete list of pipeline products, please go to http://www.nabi.com/pipeline/index.php" target="_blank" rel="nofollow ugc noopener">http://www.nabi.com/pipeline/index.php . The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website at http://www.nabi.com .


Source: Nabi Biopharmaceuticals


Mail to Friend Email Story

Alerts Set News Alert

Printer Version Print Story

Sponsor Results
Personal Finance Guide
Hot stock picks for tomorrow. Penny stock tip investments, undervalued situations, IPOs, obscure penny stocks, and other great stock picks. Free report.
www.rocketstockpicks.com
Personal Finance and the Stock Market
Learn how to invest wisely and successfully in `The Little Book that Beats the Market`, by top performing hedge fund manager Joel Greenblatt.
www.littlebook.com
Personal Finance at Scottrade
Track an unlimited amount of stocks in real-time in your Scottrade personal portfolio. Online trades just $7 per trade, no share limits. Personal brokers in offices nationwide. Apply online.
www.scottrade.com
(What`s This?)


http://biz.yahoo.com/prnews/060303/flf006.html?.v=44

[nkelchen]

gerade über 4,60!!!!



ENDLICH GEHT ES RICHTIG LOS!!
nk

[nkelchen]

[posting]20.599.808 von nkelchen am 09.03.06 16:28:56[/posting]

Dat isset:
-----------

Press Release Source: Nabi Biopharmaceuticals


Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for NicVAX(R)
Thursday March 9, 10:26 am ET


ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI - News) today announced that NicVAX® (Nicotine Conjugate Vaccine), the company`s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA).
ADVERTISEMENT


Under the FDA Modernization Act of 1997, Fast Track regulations facilitate the development of products that treat serious diseases where an unmet medical need exists. Fast Track regulations are also designed to expedite the review process for designated products, including the potential for companies to ask for priority review.

"We believe this is the first Fast Track Designation for a smoking cessation product candidate, which is unprecedented, and provides further validation for our unique approach to addressing nicotine addiction," stated Henrik S. Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, Nabi Biopharmaceuticals. "Smoking is the number one preventable cause of death in the western world, yet current smoking cessation therapies do not effectively treat the root cause of the addiction. We believe the vaccine approach inherent to NicVAX will provide clear patient advantages and a strong differentiation from currently marketed and development-stage products."

How NicVAX is Designed to Work

NicVAX is designed to cause the immune system to produce antibodies that bind to nicotine and prevent it from entering the brain. It is believed that these nicotine antibodies will act like a "sponge" soaking up nicotine as it circulates in the bloodstream and preventing it from reaching the brain. The positive stimulus in the brain that is normally caused by nicotine is no longer present, thereby eliminating the addictive properties of smoking and, consequently, helping people to quit. Unlike current therapies, such as nicotine patches and gums, smokers will not be able to eliminate the effects of NicVAX by stopping their treatment. In addition, because these antibodies are expected to be long lasting, it is believed NicVAX will also be effective in preventing smoking relapse, a significant challenge with existing smoking cessation therapies.

Progress to Date and Next Steps

Nabi Biopharmaceuticals has completed four Phase I/II studies, totaling close to 200 patients, for NicVAX. These studies demonstrated that NicVAX is well tolerated, highly immunogenic, produced dose-dependent increases in antibody titers, and showed a good indication of efficacy at the 200 ug dose with a 33 to 40 percent quit rate versus nine percent for smokers dosed with a placebo.

In September 2005, Nabi Biopharmaceuticals announced that it had received a $4.1 million grant by the U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, for partial funding of the development program for NicVAX. Partnering remains Nabi Biopharmaceuticals` strategic goal for NicVAX.

Nabi Biopharmaceuticals will next conduct a Phase II "proof-of-concept" study for NicVAX, which is expected to commence during the second quarter of 2006. The study will be comprised of approximately 300 patients, a large enough sample size to establish both proof-of-concept and optimal dose identification for the company`s Phase III program. The study results are anticipated in the second half of 2007.

Importantly, the vaccine manufactured for this Phase II study has been manufactured at commercial scale in an optimized formulation at the company`s vaccine manufacturing facility in Boca Raton, Florida. This further demonstrates the significant advancements that have already been achieved in the development of Nabi Biopharmaceuticals` nicotine addiction program. The study design will incorporate recommendations from a newly formed scientific advisory panel. The panel is comprised of scientific and clinical experts in smoking cessation. The panel will also provide input to the company on other aspects of the NicVAX development program.

Nabi Biopharmaceuticals has also met with the FDA, as well as the European Medicines Agency (EMEA), to ensure all key regulatory requirements are built into the NicVAX Phase II trial design and overall development program.

Cigarette Smoking: A Growing Global Health Challenge

Smoking is a global healthcare problem, and The World Health Organization estimates that there are 1.3 billion smokers worldwide and nearly five million tobacco-related deaths each year. According to the U.S. Centers for Disease Control and Prevention (CDC), tobacco use is the single leading preventable cause of death in the United States and is responsible for more than 440,000 deaths each year. They estimate that approximately 70 - 80 percent of smokers in the U.S. want to quit, but less than five percent of those who try to quit remain smoke-free at 12 months. In addition, they estimate that tobacco use causes $75.5 billion in excess medical costs and $81.9 billion in illness- related productivity losses each year in the U.S. To learn more about NicVAX and how it works, please visit our website at: http://www.nabi.com/pipeline/pipeline.php?id=3" target="_blank" rel="nofollow ugc noopener">http://www.nabi.com/pipeline/pipeline.php?id=3 .

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology) and nicotine addiction. For a complete list of pipeline products, please go to http://www.nabi.com/pipeline/index.php" target="_blank" rel="nofollow ugc noopener">http://www.nabi.com/pipeline/index.php . The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website at http://www.nabi.com .

Forward-Looking Statement

Statements in this press release about the company that are not strictly historical are forward-looking statements and include statements about our marketed products, products in development, demand for our products, clinical trials and studies, licensure applications and approvals, assessment of the StaphVAX Phase III trial results, and alliances and partnerships. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to the company`s ability to advance the development of products currently in the pipeline or in clinical trials; complete the assessment of the StaphVAX Phase III clinical trials during the first half of 2006; maintain the human and financial resources to commercialize current products and bring to market products in development; obtain regulatory approval for its products in the U.S., Europe or other markets; successfully develop, manufacture and market its products; realize future sales growth for its biopharmaceutical products; prevail in patent litigation; raise additional capital on acceptable terms; re-pay its outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company`s Annual Report on Form 10-K for the fiscal year ended December 31, 2005 filed with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: Nabi Biopharmaceuticals

[nort.]

[posting]20.599.876 von nkelchen am 09.03.06 16:31:36[/posting]na wenn das keine Kaufgründe sind

[nort.]

NicVAX®

Nabi Biopharmaceuticals is developing NicVAX® (Nicotine Conjugate Vaccine) a novel and proprietary investigational vaccine to prevent and treat nicotine addiction and as an aid to smoking cessation. NicVAX is designed to cause the immune system to produce antibodies that bind to nicotine and prevent it from entering the brain. We believe that these nicotine antibodies will act like a "sponge" soaking up nicotine as it circulates in the blood stream and preventing it from reaching the brain. The positive stimulus in the brain that is normally caused by nicotine would then no longer be present. Preclinical studies showed that vaccination with NicVAX can prevent nicotine from reaching the brain and block the effects of nicotine, including effects that can lead to addiction or can reinforce and maintain addiction.

Market

Tobacco use is the single leading preventable cause of death in the United States and is responsible for more than 440,000 deaths each year.1 According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 49 million adults and 6 million teenagers in the U.S. smoke, triggering an estimated $75.5 billion in excess medical costs and another $81.9 billion in mortality-related productivity losses each year .1 Despite widespread knowledge of tobacco`s dangerous health effects, smoking continues to pose a serious public health threat as the number of teenage smokers increases and others are unable to quit due, in large part, to tobacco`s addictive properties. According to the CDC, an estimated 70 percent (32.2 million) of smokers want to quit, but only 2.5 percent (1.2 million) per year succeed in quitting permanently.2

NicVAX is being developed to help the millions of patients in the U.S. and potentially billions worldwide who are addicted to tobacco products, or are at risk of becoming addicted.

1. MMWR - Annual Smoking - Attributable Mortality, Years of Potential Life Lost and Economic Costs - United States 1995-1999, April 12,2002/Vol.51/No.14

2. National Center for Chronic Disease Prevention and Health Promotion, Tobacco Information and Prevention Source (TIPS). Management of Nicotine addiction Fact Sheet.

http://www.nabi.com/pipeline/pipeline.php?id=3

[nort.]

[nort.]

Shorts are Covering
by: mikegbe1164
Long-Term Sentiment: Buy 03/09/06 03:25 pm
Msg: 37232 of 37234

27% less shorts this month than last month. Check it out
http://www.shortsqueeze.com/index.php?symbol=nabi

[nort.]

Impfung gegen Nikotinsucht in der zweiten Phase

Nabi Biopharmaceuticals gibt Abschluss der Probandengewinnung für die klinische Phase-II-Studie mit NicVAX(TM) bekannt

1.07.2005 - Bray, Irland. Nabi Biopharmaceuticals gab bekannt, dass das Unternehmen die Probandengewinnung für ihre in Europa durchzuführende Phase-II-Studie mit NicVAX(TM) (Nikotinkonjugat-Vakzin) in unterschiedlichen Dosierungen unter Rauchern abgeschlossen hat. NicVAX ist ein neuartiger, innovativer, proprietärer, in der Untersuchungsphase befindlicher Impfstoff, der für die Prävention und Therapie von Nikotinsucht entwickelt wird.

Die Studie soll die Sicherheit von NicVAX und die Antikörperreaktion auf Nikotin untersuchen und die Raucherentwöhnung bzw. die Nikotinabhängigkeit messen. Sie ist als randomisierte Studie zur Untersuchung unterschiedlicher Dosierungen bei Rauchern ausgelegt. Die vier NicVAX-Dosierungen (100, 200, 300 und 400 Mikrogramm je Injektion) werden über einen Zeitraum von sechs Monaten jeweils 10 Patienten je Dosisgruppe verabreicht. Auf Grundlage bisher beobachteter Ergebnisse klinischer Studien hat Nabi Biopharmaceuticals bis zur Dosis von 200 Mikrogramm keine signifikante Toxizität verzeichnet. Die aktuelle Studie ist daher zur Beantwortung der Frage konzipiert, ob höhere NicVAX-Dosierungen den Anti-Nikotin-Antikörperspiegel ohne höhere Toxizität noch weiter steigern könnten.

"Laut Schätzungen werden im kommenden Jahr weltweit vier Millionen Menschen an den Folgen ihres Tabakgenusses sterben", so Thomas H. McLain, Vorsitzender, CEO und Präsident des Unternehmens. "NicVAX von Nabi Biopharmaceuticals bietet in drei wichtigen Bereichen von kommerziell strategischer Bedeutung mögliche Vorteile: Der Impfstoff scheint auch in einer Dosis von 200 Mikrogramm, der höchsten getesteten Dosis, gut verträglich zu sein, und wir können daher höhere, potenziell noch wirksamere Dosierungen testen. Unser einzigartiger, proprietärer NicVAX-Wirkungsmechanismus, der mit demselben Trägerprotein arbeitet, das wir auch in StaphVAX einsetzen, ist bewährt, und schliesslich sind wir überzeugt, dass NicVAX das fortschrittlichste Produkt ist, das sich derzeit zur Raucherentwöhnung in der Entwicklung befindet. Bis Ende 2005 möchten wir vorläufige Ergebnisse dieser europäischen Phase-II-Studie bekannt geben, in der Lage sein, eine zentrale europäische Phase-III-Studie einzuleiten, und die Produktion kommerzieller Materialmengen in unserer eigenen Anlage zur Herstellung von Impfstoffen in Boca Raton, Florida, aufnehmen."

Bisher positive klinische Resultate

Nabi Biopharmaceuticals gab im September 2004 die Ergebnisse einer US-amerikanischen Phase-II-Studie mit NicVAX bekannt. Diese zeigten bei mit der höchsten NicVAX-Dosis behandelten Rauchern eine Entwöhnungsquote von 33 Prozent. Die Vergleichsquote für die Placebogruppe betrug 9 Prozent. Dieser Effekt wurde nur mit NicVAX ohne zusätzliche Interventionen, ergänzende Behandlungen, unterstützende Verhaltensschulungen oder Beratungen erzielt. (In einer Studie zu einer Konkurrenztherapie, bei der die Impfstoffbehandlung durch psychologische Beratung ergänzt wurde, erzielte die Placebogruppe 31 Prozent.)

Ziel der US-amerikanischen Studie war es zu zeigen, dass NicVAX bei Rauchern auf sichere Art und Weise nikotinspezifische Antikörper erzeugen kann, und den potenziellen Einsatz des Produkts in der Unterstützung bei der Raucherentwöhnung zu beurteilen. Die Raucherentwöhnung wurde durch Untersuchungen des Cotinin- und Kohlenmonoxidspiegels, zweier biochemischer Marker des Nikotinkonsums, bestätigt. Nikotinabhängigkeit wurde mit Hilfe eines Fragebogens gemessen. Auch bei der höchsten NicVAX-Dosis wurde im Vergleich zum Placebo oder niedrigeren Dosierungen ein beträchtlicher Rückgang beobachtet.

Dr. Henrik S. Rasmussen, Ph.D., Senior Vice President, klinische, medizinische und aufsichtsbehördliche Angelegenheiten, kommentierte: "Um klinisch erfolgreich zu sein, müssen Ansätze für die Raucherentwöhnung sicher und wirkungsvoll sein und zu langfristigem Einstellen des Rauchens führen. Auf Grundlage bisher beobachteter klinischer Resultate sind wir überzeugt, dass NicVAX für die Erreichung dieses Ziels gut positioniert ist. Wir konnten auch eine Korrelation zwischen Titerspiegeln an Anti-Nikotin-Antikörpern und der Raucherentwöhnung beobachten. Wir sind daher der Meinung, dass noch höhere Dosierungen bei Rauchern mit potenziell grösseren Antikörperreaktionen verbunden sein könnten. Wir sind der Ansicht, dass die Ergebnisse der NicVAX-Studie zur Dosisoptimierung weitere zwingende Hinweise darauf ergeben werden, dass ein Impfstoffansatz für die Raucherentwöhnung nicht nur praktikabel ist, sondern NicVAX Rauchern auch dringend benötigte Unterstützung bietet und langfristige Entwöhnung, geringeren Zigarettenkonsum und weniger Nikotinabhängigkeit fördert. Wir erwarten, dass diese Studie eine wichtige Basis schaffen wird, von der aus wir unsere für den weiteren Verlauf dieses Jahrs geplanten zentralen Studien zur Wirksamkeit konzipieren und weiter vorantreiben können."

Einzigartiger Wirkungsmechanismus

NicVAX ist ein Nikotinderivat, das mit Hilfe der patentierten Vakzintechnologie von Nabi Biopharmaceuticals chemisch an ein speziell ausgewähltes Trägerprotein gebunden wird.

NicVAX veranlasst das Immunsystem zur Produktion von Antikörpern, die sich an Nikotin binden und so verhindern, dass Nikotin ins Gehirn eintritt. Es wird angenommen, dass diese Nikotinantikörper im Blut zirkulierendes Nikotin ähnlich wie ein Schwamm aufsaugen und es so nicht ins Gehirn gelangen lassen. Der von Nikotin normalerweise im Gehirn ausgelöste positive Reiz fehlt daher, und es besteht so keine physische Motivation mehr für das Rauchen. Dies macht es Menschen folglich einfacher, mit dem Rauchen aufzuhören.

Laut Studien kann eine Impfung mit NicVAX verhindern, dass Nikotin ins Gehirn gelangt, und Wirkungen von Nikotin blockieren, auch Wirkungen, die Sucht verursachen, verstärken oder aufrecht erhalten.

http://www.bionity.com/news/d/47785/?ps=&pw=a&t=&defop=and&w…

[nort.]

Barchart full green. We are on track

http://quotes.barchart.com/texpert.asp?sym=nabi

[nkelchen]

[posting]20.647.823 von nort. am 12.03.06 12:30:25[/posting]

Ja, sieht schon immer besser aus.

Gruss
nk
*wo sind nur die ehemaligen Board shareholder geblieben*

[nort.]

wird schön nach Oben durchgereicht

[nkelchen]

[posting]20.703.658 von nort. am 15.03.06 17:22:22[/posting]
und bis "oben" ist noch viel Luft!!


Gruss
nk

[Mannitrader]

Heute über 5,00 Dollar!!!

Geht jetzt geht es richtig los...

Gruß Mannitrader

[Muggeli]

Nachbörslich in USA gerade 5,52 - gibt´s was neues???

(bin seit dem Crash zu 2,92 € dabei )

[Glück]

[posting]20.742.342 von nkelchen am 16.03.06 20:26:50[/posting]Mir hat einer rübergeschaufelt, dass das reinste Biotechqualität sein soll....

[Muggeli]

Ahhhh....:

Nabi To Continue Developing Gram-Positive Program




03-21-06 05:22 PM EST
Dow Jones Newswires

After the closing bell, Nabi Biopharmaceuticals (NABI) said it will continue developing its Gram-positive program, led by StaphVAX and Altastaph.

Nabi`s decision was based on an outside advisory panel`s review of the company`s assessment of the StaphVAX confirmatory Phase III clinical study results.

Nabi added that the assessment revealed marked differences in the effectiveness of the lot of the vaccine used in the study compared to the lot used in the previous Phase III clinical study.

Nabi shares traded at $5.32 after hours on Tuesday, up 11% from the closing price of $4.80.

-Ruth Mantell; 415-439-6456; [e-mail]

[nkelchen]

[posting]20.899.074 von Glück am 21.03.06 23:09:28[/posting]

schön, dass das Glück nun auf unserer Seite ist.
nk

*eigentlich mag ich keine BIO-Werte, aber diese Rebound Chancen gibt es nur hier..*

siehe:
Thread: The fallen Angel...( Biotech-Rebound Depot )

[Glück]

[posting]20.901.920 von nkelchen am 22.03.06 09:30:04[/posting]Schade, das im Vergleich zu NVAX z.B. nur wenige Stücke über den Tresen gehen....

[Freestyler2001]

Steil bergauf gehts mal wieder, da wird einem ja Angst und Bange bei der Geschwindigkeit, aber nun gut das Ziel von 10€ ist nicht mehr unrealistisch, dabeibleiben Nabilaner und Gewinne laufen lassen

[nort.]

Ein schöner Abschluß am Freitag. Nächste Woche sollte es weiter bergauf gehen.

[nort.]

Antwort auf Beitrag Nr.: 20.902.177 von Glück am 22.03.06 09:39:28

kommt Zeit, kommt Volumen

[loseit]

NABI hat den schnellen Anstieg in einem Tag konsolidiert und ist jetzt schon wieder auf dem Weg nach oben!

Wenn es plausible (und abstellbare!) Erklärungen gibt für das Versagen von Staphvax gibt, sehe ich den Kurs bei 8 $ bis Sommer;

habe wieder aufgestockt und tue das weiter, wenn heute kein Doppeltop kommt.

Gruss Loseit

[cyberhai]

Neues von NABI:

http://biz.yahoo.com/prnews/060403/flm025.html?.v=22

Gruß Cyberhai

[nort.]

Antwort auf Beitrag Nr.: 21.061.208 von cyberhai am 03.04.06 22:06:20

na dann, lass mal steigen

[Moz68]

Nachbörslich $5.68 (+4.03%)!

[HSM]

Servus allerseits



Aus "Der Aktionär" - Mehr aus der aktuellen Ausgabe siehe Thread: ►Der Aktionär Empfehlungen 15/2006 ◄



Top-Tipp spekulativ: Nabi Biopharma, Kursziel 9 Euro.

[dl9baf]

Antwort auf Beitrag Nr.: 21.066.969 von HSM am 04.04.06 13:08:32

Erst mal alle raus und dann gehts weiter ,,,,,,,,,,,,

[nort.]

steigt und steigt und keiner mehr da?

[nkelchen]

Antwort auf Beitrag Nr.: 21.096.244 von nort. am 06.04.06 07:29:28

in der Ruhe liegt die Kraft!
Übrigens,
erste Positionen in OLGC aufgebaut...

Gruss
nk

[loseit]

Antwort auf Beitrag Nr.: 21.096.780 von nkelchen am 06.04.06 08:53:27

Hi nk,

Du hattest mit NABI 'nen guten Riecher,
ich bin zum Grossteil zu früh raus, aber noch vertreten.
Die einzige erfreuliche Position im Moment

Gruss Loseit

[nkelchen]

Antwort auf Beitrag Nr.: 21.097.830 von loseit am 06.04.06 09:53:58

schön, dass Du noch dabei bist.
Ausser meinem Rebound Depot, läuft bei mir zur Zeit auch nix.
Hoffentlich laufen die Neuaufnahmen so gut, wie NABI, SCLN, PCYC oder RIGL.

Gruss
nk

[loseit]

Antwort auf Beitrag Nr.: 21.097.893 von nkelchen am 06.04.06 09:56:48

Hi nk,

gerade meine Rebounds laufen nicht!

Allerdings laufen sie dann meist, wenn ich aus Frust ausgestiegen bin.

Darum bleibe ich jetzt mal länger drin und gucke hier einfach mal seltener rein...

Bis dann

Loseit

[johnnt]

ist zwar nicht viel los hier, die aktien scheint noch nicht vielen aufgefallen sein.
aber ich glaube (hoffe ;-)) die kommt noch richtig anständig.

[2014]

Wahrscheinlich lesen die Leute den "Aktionär" als Wochenendlektüre.

Anders sind die Stückzahlen nicht zu erklären. Wichtig ist aber,

dass in NY schon seit Wochen super Stückzahlen gehandelt werden.

Werte die nur in Deutschland gepuscht werden, sind wesentlich

anfälliger.

[nkelchen]

Antwort auf Beitrag Nr.: 21.107.219 von 2014 am 06.04.06 17:51:51

NABI ist ein reiner Ami Wert.
Da können die selbernannten Anals in Germany trommeln,
oder sonst was dahin schmieren...
Kalter Kaffee ist gehaltvoller!

Gruss
nk

[loseit]

Antwort auf Beitrag Nr.: 21.109.717 von nkelchen am 06.04.06 19:52:32

Die Konsolidierung der letzten Tage war erträglich - Bullenflagge seitwärts.

Bald zündet die nächste Stufe!

Gruss Loseit

[2014]

NY wieder 7 cent im Plus - FFM liegt unter Kurs

[Muggeli]

6$ geknackt in Amiland!

[nort.]

Antwort auf Beitrag Nr.: 21.124.770 von Muggeli am 07.04.06 18:25:17

dann greifen wir doch jetz mal die 8$ an

[cyberhai]

Trotz schlechtem Umfeld, macht sich Nabi bestens

Gruß Cyberhai

[nort.]

4,466,900 shares sind geshorted mal sehen ob vor dem WE noch Kaufdruck aufkommt...

[nort.]

Infos zu NicVax & NABI

http://www.wallstreet-online.de/community/thread/903455-16.h…

[nort.]

Nabi Biopharmaceuticals Exhibits at Bio 2006
Sunday, April 9, 2006 through Wednesday, April 12, 2006

Event Details
Title Nabi Biopharmaceuticals Exhibits at Bio 2006
Date and Time Sunday, April 9, 2006 through Wednesday, April 12, 2006
Location Chicago, IL
Description Corporate

mal sehen, ob hier was durchsickert...

[nort.]

@zenman - Titel passt

Nabi Biopharmac. ein Investment

11.04.2006 16:20:09

Nach Ansicht der Experten des Börsenbriefs "Biotech-Report" ist die Nabi Biopharmaceuticals-Aktie (ISIN US6295191091/ WKN 856797) ein Investment.

Das Unternehmen habe Ende Oktober letzten Jahres seine klinischen Studien mit experimentellen Wirkstoffen gestoppt, die gegen sogenannte Gram-positive Bakterien eingesetzt werden sollten. Wesentliche Ziele seien bei den Tests verfehlt worden. Das Papier habe anschließend fast 70% an Wert verloren. Ein vom Managment beauftragtes Expertenteam habe dann aber herausgefunden, dass die schlechten Ergebnisse nicht auf die Produktkandidaten selbst, sondern im Wesentlichen auf äußere Umstände zurückzuführen seien. Die Gesellschaft habe sich vor kurzem entschlossen, die Tests wieder aufzunehmen.

In letzter Zeit würden sich die guten Nachrichten bei dem Unternehmen häufen. Jüngst habe Nabi einen Deal mit Fresenius gemeldet, nachdem man von einer Fresenius-Tochter die Rechte an einem Phase-III-Produkt übernehmen werde, mit dem Abstoßreaktionen nach Transplantationen verhindert werden sollten.

Dies sei nach Ansicht der Experten von "Biotech-Report" ein Grund mehr, der für ein Investment in die Nabi Biopharmaceuticals-Aktie spricht.

Analyse-Datum: 11.04.2006

http://www.aktienresearch.de/analysen/analysen_detail.asp?An…

[jeo1]

Liebe Bordmitglieder,

werde heute meine Nabi Aktien gewinnbringend verkaufen (Einstiegskurs 3,16 Dollar) und in Inhibitex (INHX) einsteigen. Heute ist der letzte Handelstag an dem ich vor Ostern handeln kann. Diese Chance lasse ich mir nicht entgehen. In den letzten Tagen ist die Aktie von 8 auf 2 Dollar gefallen und das völlig übertrieben.

Das Medikament befindet sich in Testphase drei. Es wurde bekannt gegeben, dass ein Test fehlgeschlagen ist. Schuld war aber nicht das Medikament sondern die Testart. In anderen Tests lieferte das Medikament signifikante Ergebnisse. Wenn Inhibitex im Tagesverlauf unter grossem Volumen auf 1,50 Dollar sinkt, so wie ich vermute, werde ich mein Glück versuchen.

[loseit]

Antwort auf Beitrag Nr.: 21.188.717 von jeo1 am 13.04.06 11:25:40

So habe ich das auch immer gemacht. Und jedesmal dabei Geld verloren.

Kleiner Tip: Guck dir die Aktie noch mindestens zwei Wochen an, ehe Du kaufst.

Gruss Loseit

[Freestyler2001]

...habe mir gerade Inhibitex angeschaut, auf den ersten Blick eine interessante Sache, jedoch muss ich meinem "Vor-Redner" Recht geben, da besteht weiterhin Potenzial nach unten, und wer weiß schon genau ob es nicht tatsächlich das Aus für das Produkt ist? Würde auch erstmal abwarten, es ergeben sich noch Chancen zum Einstieg wenn ein Boden gefunden ist...wie bei Nabi damals, ich halte Nabi derzeit für sehr interessant wir bewegen uns auf die 200Tage Linie zu, ein harter Brocken, der früher oder später aber fallen wird...und dann die Sache mit dem Präparat gegen das Rauchen, viel viel Potenzial nach oben...halten halten halten, damit das Finanzamt leer ausgeht=)

[jeo1]

Antwort auf Beitrag Nr.: 21.209.560 von Freestyler2001 am 16.04.06 16:53:17

Glückwunsch an die, die INHX in Deutschland bekommen haben. Bald decken sich die Shorties in den USA wieder ein. Der RSI steht bei 9 - ein unglaublicher Wert.


Tax Code - Wash Sale Rule

A "wash sale" describes the situation in which you sell shares of some security at a loss, and within 30 days you purchase substantially identical securities. At face value, it looks like you took a loss on an investment (would would be deductible from your gross income when you do your taxes), yet you still own that investment, you just now have a lower cost basis. Unfortunately, the IRS does not consider the loss resulting from such a transaction to be deductible. If a sale is considered to be a wash sale, the loss cannot be treated as a capital loss on your federal tax return. In fact, the cost basis of the securities purchased is increased by the amount of that disallowed loss. The goal is to prevent someone from converting a paper loss into a real loss while actually hanging onto that same position.


Wash Sales:
You cannot deduct losses from wash sales or trades of stock or securities. However, the gain from these sales is taxable.

A wash sale occurs when you sell stock or securities at a loss and within 30 days before or after the sale you buy or acquire in a fully taxable trade, or acquire a contract or option to buy, substantially identical stock or securities. If you sell stock and your spouse or a corporation you control buys substantially identical stock, you also have a wash sale. You add the disallowed loss to the basis of the new stock or security.

This rule includes normal purchases followed by sales (i.e., you go long, then sell at a later date) as well as short sales and later purchases

written by bigtouble

[Freestyler2001]

Nabi bekommt neuen Schwung->4,96€ in FSE, vorbörslich gehts in den USA rund Bid 6,23 Ask 6,50 ein satter Aufschlag zum gestrigen Tag, vielleicht gibts News.

[nkelchen]

Antwort auf Beitrag Nr.: 21.219.989 von Freestyler2001 am 18.04.06 09:53:40

ist schon merkwürdig,
da ist Monate lang kaum Umsatz in Deutschland,
dann kommen Empfehlungen und Umsätze.
Allerdings sind die Balken rot -
wollte da wer raus, der dummerweise in old Germany, anstatt
in USA gekauft hatte?

[nkelchen]

Antwort auf Beitrag Nr.: 21.220.548 von nkelchen am 18.04.06 10:36:41

darum also 500k in 1,5Minuten gehandelt:

Hot Stocks to Watch for Tuesday, April 18, 2006: Taking on North American Consumers!
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.
WESTON, FL -- (MARKET WIRE) -- 04/18/2006 -- TheSUBWAY.com announces the following stocks to its Hot Stocks List: Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), Streicher Mobile Fueling, Inc. (NASDAQ: FUEL), Nabi Biopharmaceuticals (NASDAQ: NABI), Blue Dolphin Energy Company (NASDAQ: BDCO).

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie sweetener (Stevia) in China, announced that its wholly owned subsidiary, Sunwin Stevia International Corp., has engaged Blue Chip Marketing and Communications to assist the company in marketing its Stevia to North American consumers.

Under the terms of the agreement, Blue Chip Marketing will create and manage a comprehensive marketing campaign designed to introduce Stevia to the mass consumer market. Major health food stores and nutritional stores have been selling Stevia in the United States for years. In the past several years, a significant number of major grocery chains have also started to market Stevia. Research indicates that sales of Stevia marketed through traditional grocery chains have increased between 100%-200% over the last two years.

Other stocks highlighted include Streicher Mobile Fueling, Inc. (NASDAQ: FUEL): Hot Stocks List, up 2% on 2 million shares, Nabi Biopharmaceuticals (NASDAQ: NABI): Hot Stocks List, up 1% on 5 million shares, Blue Dolphin Energy Company (NASDAQ: BDCO): Hot Stocks List, down 3% on 2 million shares.

"A few disappointing earnings releases and some disparate economic data have done their part to stall the market's advance, and political developments abroad have kept investors cautious. But overall tame inflation numbers, though rising over the past few months, solid growth in the domestic economy, and lower unemployment are buffeting the averages from below." More is available at: http://www.thesubway.com.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated twenty five thousand dollars for SUWN. CRG has received two hundred thousand shares in past compensation for SUWN, and has sold all of those shares. CRG intends to sell its shares. CRG has sold approximately zero SUWN shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.





--------------------------------------------------------------------------------


Chuck Tamburello
Phone: [phone]
Fax: [phone]


SOURCE: TheSUBWAY.com

--------------------------------------------------------------------------------

Back To Recent News
Issuers of news releases, not Market Wire, are solely responsible for the accuracy of the content.

[nkelchen]

Antwort auf Beitrag Nr.: 21.224.678 von nkelchen am 18.04.06 15:34:53

das war aber nu knapp -
hatte meine NABI vorbörslich zu 5,99 verkloppt
und wollte dann später wieder günstiger rein.
Das hat schon ein paar Male geklappt.
Nur heute ging es voll in die Hose!
Und dann hat mir eben doch einer nachbörslich welche zu 5,92 geschenkt

Fazit:
Schwein gehabt!
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.224.678 von nkelchen am 18.04.06 15:34:53

hier der Beleg


nk

[nort.]

NABI's Situation - Then and Now
by: will_i_am7788
Long-Term Sentiment: Strong Buy 04/18/06 09:11 pm
Msg: 43082 of 43102

On Nov. 1,2005 NABI's stock price dropped from $12.85/share (Market close on Oct. 31st) to $3.63/ share close on 55+ million shares traded due to the StaphVax phase III confirmation test failure. A loss of $9.22/share. On March 22, 2006 NABI's stock rose from $4.80/share (Market close on March 21st) to $5.76/share close on 16+ million shares on the news that StaphVax was not a failure, but was indeed a viable vaccine as ALL previous tests had shown (This restoration to a viable vaccine HAS NOT YET BEEN RECOGNIZED!!!).

In the previous two+ years (Before Nov. 1, 2005) I have heard of a poison pill of $70/share mentioned may times (I cannot verify it's existence). The purpose of that poison pill (According to the Message Board posters) was to prevent a hostile takeover of the company for peanuts ($10 - $20 . . . . $70/share). NABI knew that they had something of great value!

Now that StaphVax (and AltaStaph) has been re-confirmed as a potential wonder vaccine/drug that will meet huge medical needs, and is being enhanced to cover not just type 5 and type 8 Staph, but almost all types of Staph, the potential value is much greater. In addition, other vaccines/drugs (Such as NicVax) have been added to the pipeline, and given fast track status, and have huge potential of their own. Granted, a delay of commercialization has occurred, but the enhanced product, and new products, have so much more value than before.

So what is the situation with NABI? The value is so much more now (and hasn't been realized) than before, and here we are talking peanuts. RIDICULUS!!! I know most of you have heard of a ten bagger. This is one if I have ever seen one. If we can just have patience we can realize the results of this greatly enhanced value. I don't blame Third Point, LLC from becoming involved. I think it is a positive development. Maybe now investors will become aware of the great value in this stock. JMHO.

Best Regards, Will

[nkelchen]

Antwort auf Beitrag Nr.: 21.233.751 von nort. am 19.04.06 07:33:08

Moin nort. -

liest sich ja alles sehr gut....,
aber wer ist Will?

Seit ich mich mit diesen Werten beschäftige und dass ist erst
seit November 2005, hat es schon 10 Werte aus dem NQBiotechindex zerlegt!
Also immer schön vorsichtig bleiben.

Gruss
nk

[nort.]

auf zu den 10$

http://www.sun-sentinel.com/business/local/sfl-znabi19apr19,…

Nabi shares jump 12% after investor buys large stake

By Glenn Singer
South Florida Sun-Sentinel
Posted April 19 2006

E-mail story
Print story
Most e-mailed
News on your cell
XML RSS news feeds



MOST E-MAILED
(last 24 hours)
1. Bombing at Tel Aviv restaurant injures Weston father, son
2. Easter Bunny charged with punching angry customer at Fort Myers mall
3. Humane Society volunteer has nose bitten off while trying to separate fighting dogs
4. Question of the day: Where is the cooling housing market headed?
5. Man shot to death by police in Margate after bullet-riddled 100 mph chase
See the complete list ...

Click here to subscribe Subscribe today to the Sun-Sentinel
and find out how to get one week extra!
Click here or call 1-877-READ-SUN.


LocalLinks
Shares of Boca Raton-based Nabi Biopharmaceuticals jumped 12 percent on Tuesday after a New York investor disclosed he has acquired a big piece of the company and urged it to hire a new investment banking firm to maximize shareholder value, including possibly arranging a sale.

Daniel Loeb, who heads Third Point LLC, reported to the Securities and Exchange Commission that he and his investment funds have purchased 5 million Nabi shares, or 8.4 percent of the outstanding shares, since Feb. 24. The first purchases were at $3.78 a share, and they continued as the price rose gradually to $5.68 on Monday, according to the SEC filing.

Nabi shares closed Tuesday at $6.32, up 68 cents, after investors read in the filing that Loeb thinks "the market price of the common stock materially understates the intrinsic value of the company's marketed products, product pipeline, intellectual property" and its plant and equipment.

Nabi's stock value disintegrated after company scientists revealed on Nov. 1 that a flagship vaccine to prevent staphylococcus aureus infections, StaphVAX, failed in a clinical trial to protect kidney patients undergoing dialysis. Shares lost 70 percent that day, sinking to $3.63 from $12.85. They continued to fall to $3.10 on Nov. 29 before starting to edge upward.

Investors received some good news when Nabi said March 21 that a manufacturing defect, coupled with a very ill patient population unable to develop sufficient antibodies from the vaccine, caused its failure. The company pledged to resume work on an improved version of StaphVAX.

Loeb, whose funds are worth some $4 billion, contended that "despite recent positive developments," Nabi does not seem likely to achieve that intrinsic value under its current strategic plan. He criticized management's "inability or unwillingness to forecast a time frame" in which to achieve positive cash flow and earnings and said Nabi should immediately retain a new investment banking firm and explore a sale of the company.

Nabi's chief executive officer, Thomas McLain, said Tuesday that he "welcomes the opinions of all shareholders" and that the management and board of directors "take fiduciary duty very seriously."

"Our independent directors have been very committed to enhancing shareholder value, and that commitment has not changed," McLain said. He would not comment on any possible sale, but stressed management has "a successful working relationship" with its investment banker, Lehman Brothers.

"We value their strategic advice," McLain said.

Described by The New York Times as "the famously outspoken hedge fund manager," Loeb has from time to time publicized letters in which he criticized chief executives for such failings as indolence and incompetence. He has on occasion pushed for his candidates to be elected to corporate boards.

On Tuesday, for example, he urged Massey Energy Co. stockholders to elect him and an associate to the board, saying they would provide "a new voice and a fresh perspective" for the Richmond, Va.-based coal mining firm.

Glenn Singer can be reached at [e-mail] or 561-243-6612.

[nkelchen]

Antwort auf Beitrag Nr.: 21.243.793 von nort. am 19.04.06 19:07:06

vorher aber bitte das Gap schliessen,
ich spekuliere mal drauf

nk

[nort.]

Antwort auf Beitrag Nr.: 21.244.047 von nkelchen am 19.04.06 19:21:58

nkelchen, jetzt sei mal nicht so kleinlich

[nkelchen]

Antwort auf Beitrag Nr.: 21.244.120 von nort. am 19.04.06 19:26:59

Was heisst kleinlich?
Ich warte an der 6 auf Euch
Die Lemminge werden nun erst einmal abgeschüttelt.
3% sind es schon
Gruss
nk

[HoTsTePPa.]

Bei 6.05 waren wir. Wann denkst du ist das Gap geschlossen?

[nkelchen]

Antwort auf Beitrag Nr.: 21.259.638 von HoTsTePPa. am 20.04.06 18:32:17

Bei 5,64 exakt.
Leider hatte ich keine Order um die 6drin.
Da wir aber intraday schon die 6 tuschiert haben,
sollte die auch das Ziel für die nächsten Tage sein..
Gruss
nk

[HoTsTePPa.]

Antwort auf Beitrag Nr.: 21.260.280 von nkelchen am 20.04.06 19:13:04

Na schauen wir mal. Bin gestern leider zu 6.58 rein. Mir wäre es lieber es geht wieder nach oben.

[nkelchen]

Antwort auf Beitrag Nr.: 18.638.053 von zenman am 07.11.05 18:48:43

March 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 4,466,900 1.60 1,729,870 2.58


February 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 4,396,767 (27.18) 2,067,591 2.13


January 2006
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 6,037,931 (7.56) 1,428,828 4.23


December 2005
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
NABI Nabi Biopharmaceuticals - Common Stock 6,531,994 (14.11) 2,856,533 2.29

mfG
nk

[HoTsTePPa.]

After Hours +5.99% auf 5,90 $

[nkelchen]

Antwort auf Beitrag Nr.: 21.265.106 von HoTsTePPa. am 21.04.06 02:19:56

Investors demand Nabi sell
By Stephen Pounds

Palm Beach Post Staff Writer

Friday, April 21, 2006

Two major investors are asking Nabi Biopharmaceuticals to sell the company as a way to recoup shareholder losses.

In the past three days, two New York-based investment firms, Knott Partners Management LLC and Third Point LLC, have criticized the Boca Raton-based drugmaker for its poor performance and questioned its strategy in documents filed with the U.S. Securities and Exchange Commission.

More business news
• Latest news, columnists
• Local stocks
• Market tools
• Mortgage rates
• Gas prices


Together, the investment firms hold 10.2 million shares of Nabi, or 18 percent of the company's stock.

A Nabi spokesman said the company "listens to all the recommendations from all our shareholders" but declined to say if Chief Executive Tom McLain and Nabi's board are considering a sale.

Investor demands to sell the company come less than six months after the company's experimental vaccine for staph infections, StaphVAX, failed in large-scale trials. Since then, Nabi (Nasdaq: NABI) shares have dipped by more than half, from a high for the past year of $15.82 a share to Thursday's closing price of $6.51.

Nabi investors are pulling no punches.

In an SEC document filed Wednesday, Anthony Campbell, a Knott general partner, said he met with Nabi executives three times in the past month over its strategy of experimental drug development in the face of mounting losses and a stagnant stock price.

"The company has on numerous occasions missed revenue projections and scientific milestones," Campbell's letter said. "The shareholders of Nabi have suffered enough."

On Monday, Third Point Chief Executive Daniel Loeb voiced similar concerns, objecting to what he called Nabi's inability "or unwillingness" to forecast a time frame for positive cash flow and earnings.

Loeb has told executives since February that management should consider a sale "in a process conducted as publicly as possible," suggesting an auction. He also asked that Nabi refrain from selling any drugs under development or partnering with another firm, said documents filed with the SEC.

McLain was unavailable for comment Thursday. But Nabi Vice President Tom Rathjen denied the company had ignored overtures from other firms.

Rathjen declined to confirm if companies have approached Nabi and wouldn't say if McLain or Nabi's board was considering a sale. He defended Nabi's strategy, saying drug development is a lengthy process.

"We do these studies in various phases. We submit that data and the (Food and Drug Administration) reviews it. It's impossible to predict precisely when products will come to market," Rathjen said.

Shares in Nabi jumped after Monday's SEC filing but fell Thursday after the Knott filing accused management of ignoring overtures for Nabi.

"The gains that you saw earlier came after the Third Point filing said they might sell, and people bought into it," said analyst Dallas Webb of Sanford Group in Boca Raton. "The second filing probably worried (investors) a bit, after someone accused them of ignoring a (potential) buyer of the company."

Still, Nabi should explore a sale, Webb said: "Their drugs in the pipeline aren't near reaching the market and the drugs that are on the market won't generate the cash flow needed."

[HoTsTePPa.]

Grossinvestoren fordern den Verkauf von NABI? Wer soll denn da kaufen. wenn Nabi in der News so runter gemacht wird?

[nkelchen]

Antwort auf Beitrag Nr.: 21.287.516 von HoTsTePPa. am 23.04.06 16:29:10

http://yahoo.reuters.com/stocks/QuoteCompanyNewsArticle.aspx…

Biopharmaceuticals signs deal with Sanofi
Wed Apr 26, 2006 8:46 AM ET
FACT BOX

NABI.O (Nabi Biopharmaceuticals)
Last: $6.39
Change: -0.03
Up/Down: -0.47%


MayAugNovFeb
Quote
Full Chart
Company Profile
Analyst Research
News for NABI.O
Nabi Biopharmaceuticals signs deal with Sanofi
Fresenius, Nabi sign transplantation product deal
NEW YORK, April 26 (Reuters) - Nabi Biopharmaceuticals (NABI.O: Quote, Profile, Research) on Wednesday said it has signed an agreement with a unit of Sanofi-Aventis Group (SNY.N: Quote, Profile, Research) relating to protection against exposure to rabies.

© Reuters 2006. All Rights Reserved.

[nkelchen]

Antwort auf Beitrag Nr.: 21.329.166 von nkelchen am 26.04.06 14:52:31

In 5Minuten von 6,10 auf 5,50
So wird ein Gap geschlossen!!
Das muss man den Amis lassen, da haben die echt ein Händchen für..
nk

[loseit]

Hi nk,

Wenn man mutig gewesen wäre, hätte man einen Abstauer reinstellen können und schnelle 10% gemacht...

Da ich vermute, dass es bei NABI nicht auf die Finanzen, sondern auf die Perspektiven ankommt, habe ich gehalten.

Kurs wird in ein paar Tagen neuen Anlauf auf die 7$ unternehmen.

Gruss Loseit

[nkelchen]

Antwort auf Beitrag Nr.: 21.349.780 von loseit am 27.04.06 17:36:55

Hi loseit,
ich hatte ein paar Tage einen Abstauber drin - nur heute nicht
Die SL sind nun abgefischt, eine gesunde Sache.

Gruss
nk

[loseit]

Antwort auf Beitrag Nr.: 21.350.041 von nkelchen am 27.04.06 17:47:43

Hi nk,

Kurs ist schon wieder oben.
Früher habe ich selbst bei solchen Gelegenheiten Geld bei SLs verloren - jetzt sollte ich mal anfangen, andere abzuschöpfen...

Neue Nachricht:

NEW YORK, April 27 (Reuters) - Activist hedge fund Third Point LLC on Thursday took aim at NABI Pharmaceuticals Inc. (NABI.O: Quote, Profile, Research), telling the drug company that it should switch financial advisors and pursue a sale, according to a regulatory filing.

New York-based Third Point, which has about $4 billion under management, disparaged NABI's "strategic missteps" and said a "long-standing relationship" with Lehman Brothers (LEH.N: Quote, Profile, Research) "will prevent the company from receiving objective advice," according to a letter filed with regulators.

Third Point, which has been active in a number of recent shareholder campaigns to boost the value of what it considers to be underperforming companies, holds an 8.7 percent stake in NABI, according to regulatory filings.

"We demand that NABI immediately retain an investment bank other than Lehman, or in conjunction with Lehman, to explore strategies to maximize shareholder value," said Daniel Loeb, Third Point chief executive, in the letter.

Boca Raton, Florida-based NABI could not immediately be reached for comment.
__________________________

maxime shareholder value! Finde ich auch!

Gruss Loseit

[loseit]

Antwort auf Beitrag Nr.: 21.363.088 von loseit am 28.04.06 13:41:18

Noch was Neues:


Nabi touts its Boca plant for manufacturing bird flu vaccine

By Glenn Singer
South Florida Sun-Sentinel
Posted April 27 2006

Nabi Biopharmaceuticals' manufacturing plant in Boca Raton could be modified to produce a vaccine to protect against avian flu should such a vaccine be developed elsewhere, the company's top science officer said Wednesday.

"If the opportunity comes, we can manufacture an avian vaccine with some modifications" to the plant, Raafad Fahim, senior vice president for research, technical and production operations, told analysts during a conference call to discuss first-quarter financial results.

The plant is geared toward making vaccines to combat bacterial infections, but with additional equipment and investment, it could be modified to produce vaccines to fight viruses including the avian flu H5N1 strain. Such a vaccine is probably several years away, Fahim said.

His comments came after Nabi announced earlier in the day that it signed an agreement with French-based Sanofi Pasteur to help produce Imogam Rabies HT, a vaccine made from human plasma that is given immediately to people exposed to the rabies virus.

Sanofi Pasteur, part of the Sanofi-Aventis Group, also is investigating the safety of a vaccine against avian influenza under funding from the National Institute of Allergy and Infectious Diseases.

Terms of the rabies vaccine deal were not disclosed, but Nabi spokesman Thomas Rathjen said it is "an exclusive agreement for this product" and that the anticipated revenue is "not insignificant."

Under the deal, Nabi will separate components of plasma containing antibodies to the rabies virus and ship the partially manufactured product to Sanofi Pasteur for completion of production at its plant in Lyon, France. A typical dose for a 100-pound person retails for about $1,200.

Nabi needs to rely on the cash flow from contract manufacturing to continue developing its own products, including a vaccine to prevent staphylococcus aureus infections and another to help smokers quit the habit.

The company suffered a major setback late last year when its StaphVAX failed in a late-stage clinical trial, resulting in unused capacity at its plant. Nabi hopes to continue developing an improved version with a partner.

On Wednesday after the close of trading, the company reported it had $51.4 million in cash and cash equivalents on April 1 to carry on research and development. That is down from $101.8 million at the end of 2005.

For the first quarter of this year, Nabi lost $18.1 million, or 30 cents a share. That compares with a loss of $15.8 million, or 27 cents a share, in the same period a year ago.
_________________________________________________________________

Es scheint mir Sinn zu machen, die Produktionsanlagen hiermit auszulasten, die ja auf absehbare Zeit kein STAPHVAX produzieren werden.

Gleichzeitig zeigt es, dass NABI an die langfristige Rückkehr glaubt, sonst hätte man die Fabrik geschlossen.

Ich mache mir eher Sorgen über den cash-burn bis dahin und frage mich, wie NABI das finanziell durchstehen will.

Das fragen sich anscheinend auch die grossen Investoren (s.u.).

Ich sehe nur einen Weg: Kapitalerhöhung.

Was meint Ihr?

Gruss Loseit

[nkelchen]

Antwort auf Beitrag Nr.: 21.363.337 von loseit am 28.04.06 13:59:25

Fundamental bin ich hier nicht bewandert.
Meine Strategie ist rein technischer Natur.
Darum baue ich auch Aktien ab, je höher der Kurs läuft.
Gruss
nk

[loseit]

Antwort auf Beitrag Nr.: 21.363.381 von nkelchen am 28.04.06 14:03:15

Wenn ich das so mache, ärgere ich mich meist hinterher, viel zu früh verkauft zu haben.

Aber ich weiss ja, Du bist ein grosser Turnaround-Fan.

Gruss Loseit

[nort.]

NABI's Sale Price
by: will_i_am7788
Long-Term Sentiment: Strong Buy 05/03/06 11:20 am
Msg: 45356 of 45361

I read posts on NABI's Message Board from time to time saying that the sale price for NABI should be $8/share, or $10/share, between $8 and $12,etc, etc. (I agree with Vac, these estimates are just too low.) Or, we have got to get the share price up because a buyout usually goes for a 50% premium to what the stock is currently priced. As I see it, these sale price estimates are not based upon an assessment of the company's worth, but rather where the stock price has been trading. Why wouldn't 50% above last years high of $16/share ($24/share) be a fair buyout price? That was the value of the company's science and pipeline (Not including NicVax) then. The stock price took a terrible drop when the StaphVax test failed, but has not recovered since they found out that they didn't make the vaccine for the test correctly. So the stock price is currently deeply discounted relative to what it used to be (Without NicVax). What it used to be was probably a reasonable stock price. Confidence in the company's science and pipeline products has not yet been restored. If NABI would do something about that (PR's, partnerships, etc) maybe the stock price would return to more reasonable values, and then maybe 50% above the current price would be reasonable.

Instead of the above, let's look at NABI's worth based upon an assessment of the relative value of the company, its science, patents, pipeline, manufacturing facilities, etc.

Recently I read an article in Business Week magazine concerning Outsourcing. One of the situations they discussed was Eli Lilly. They said that Lilly had brought eight major drugs to market over the last five years at an average investment of $1.1 BILLION each, and that the cost in four years would be $1.5 billion each, if they did not utilize outsourcing. So, what if they just bought NABI for $1.5 billion? They would have a pipeline of drugs to meet huge unmet medical needs that nobody else has been able to meet. Plus all of the company's assets - patents, science, manufacturing facilities, collection centers, valuable scientific personnel, etc. That would be a buyout price of about $25/share, which, I believe, should be the minimum. I believe that the Hedge Funds see this kind of value in NABI shares also, and that is why they are involved. I don't believe they are here for only $5 or $6 per share profit. I further believe that if NABI was put up for sale, a number of Big Pharma companies would also see this value and bid up the price. JMHO.

So, in conclusion, my estimated Buyout price for NABI is $25/share minimum.

Best regards, Will

[nkelchen]

Antwort auf Beitrag Nr.: 21.419.929 von nort. am 03.05.06 18:01:14

hoffentlich ist das nur eine Konsi, die der BIO-Index da gerade durchmacht...


Nabi hält sich ja wirklich Klasse.


RIGL habe ich heute verkauft.

Gruss
nk

*INHX dürfte langsam spannend werden - es gab Insiderkäufe*

[loseit]

Antwort auf Beitrag Nr.: 21.419.929 von nort. am 03.05.06 18:01:14

Der Anstieg ist beeindruckend und rührt wohl hauptsächlich von den Verkaufsgerüchten. Untenstehende Argumentation finde ich schlüssig - wenn Hedgefonds den Verkauf fordern, dann stellen sie sich sicher mehr vor als den aktuellen Aktienkurs.

Gruss Loseit

[nkelchen]

Schade zen,

Thread eröffnet von:zenman
am:07.11.05 18:48:43

ein halbes Jahr Geduld, hätten 100%gebracht.
Wenn Du hier vorbeischaust, INHX ist wieder so eine Chance.
Gruss
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.433.441 von nkelchen am 04.05.06 18:11:50

hier das Bildchen dazu..



nk

[nort.]

nk,

kann bei INHX keine Insiderkäufe finden. Wo hast Du diese Infos her?

http://www.secform4.com/insider/showhistory.php?cik=inhx

nort

P.s. Prosit auf NABI and see you @10$

[Muggeli]

Antwort auf Beitrag Nr.: 21.433.441 von nkelchen am 04.05.06 18:11:50

Ja, wirklich schade das der Zen nicht mehr dabei ist, durch ihn bin ich auf Nabi gekommen und immer noch mit KK 2,92 dabei

Leider nur mit 1000 Stck.

Verfolge den Thread aufmerksam und bin auf nk´s Tipp nun auch bei INHX dabei...

Hoffen wir mal das es da auch so erfreulich läuft wie hier - und wenn´s etwas länger dauert, kein Problem - Geld hat schliesslich kein verfallsdatum!

[nkelchen]

Antwort auf Beitrag Nr.: 21.434.195 von Muggeli am 04.05.06 19:03:47

Willkommen im Biotech Sumpf!

Hoffen wir mal das es da auch so erfreulich läuft wie hier - und wenn´s etwas länger dauert, kein Problem - Geld hat schliesslich kein verfallsdatum

Euro bei 1,27

leider verfällt da schon etwas der Wert ...
die Dinger kann man in FFM ja kaum handeln.
Eigentlich müsste ich mir einen €/$ Kontrakt besorgen
nk

[nkelchen]

Antwort auf Beitrag Nr.: 21.433.704 von nort. am 04.05.06 18:30:00

da habe ich mich im INHX Treat auf`s Glatteis führen lassen.
Das sind ja nur Optionen gewesen!
Kam mir auch so merkwürdig vor, sorry nort.!!
Gruss
nk

[nort.]

Antwort auf Beitrag Nr.: 21.436.128 von nkelchen am 04.05.06 20:56:33

kein Problem nk, war kurzzeitig auch Sollten die ersten auftauchen, bin ich dabei

[nkelchen]

Antwort auf Beitrag Nr.: 21.433.704 von nort. am 04.05.06 18:30:00

Danke für den Link -
Klasse Seite!
nk

[nort.]

So jetzt sieht der Chart auch wirklich überzeugend aus



nort

[nort.]

und das Beste dabei ist, dass die NicVax Phantasie kaum drin ist

[nort.]

War alles nur ein großes Mißverständnis?

STAPHVAX WORKS: continued
by: jklbuilder49 (56/M/se florida)
Long-Term Sentiment: Strong Buy 05/06/06 07:18 am
Msg: 46059 of 46067

"I talked to an industry expert who said STAPHVAX was a VIABLE product, but (Nabi scientests) were using the wrong patients. Said Anthony Campell, a general partner with NY based Knott Partners. "STAPHVAX might already be on sale to clinics and hospitals if the Merck deal had gone through"
I posted previous STAPHVAX WORKS under Jozer123, my brother had his id up when i posted..

Wenn das wahr ist, sollten die "alten" Regionen wieder nahe sein + zusätzlich die NICVAX Phantasie!!!

http://www.palmbeachpost.com/search/content/business/epaper/…


nort

[loseit]

Antwort auf Beitrag Nr.: 21.455.136 von nort. am 06.05.06 16:36:27

Hi nort.,

klasse Recherche!

Das ist ja ein Hammer und erklärt den guten Anstieg der letzten Wochen! Insider haben das natürlich schon immer gewusst...

Damit ist tatsächlich wieder die volle Phantasie im Titel!!

[nort.]

Antwort auf Beitrag Nr.: 21.469.495 von loseit am 08.05.06 08:56:30

Hallo loseit,

beachte mal die grünen Peaks im Volumen

nort

[johnnt]

danke nort. für die infos.....ich hoffe es stimmt und wir sehen die € 10,--

danke

[nort.]

Antwort auf Beitrag Nr.: 21.485.201 von johnnt am 09.05.06 09:59:27

hoffe ich doch ebenfalls. Aber folgendes nicht aus den Augen verlieren:

...NicVAX das fortschrittlichste Produkt ist, das sich derzeit zur Raucherentwöhnung in der Entwicklung befindet.

http://www.bionity.com/news/d/47785/?ps=&pw=a&t=&defop=and&w…

96% BUY !!!!

http://quotes.barchart.com/texpert.asp?sym=nabi

[johnnt]

schade ist nur das die umsätze hier in deutschland nicht vorhanden sind.

[loseit]

Antwort auf Beitrag Nr.: 21.481.759 von nort. am 08.05.06 22:22:44

Hi nort,

das ist ein sauberer Aufwärtstrend mit kleinen Rücksetzern und Pausen.

Hier zwischendurch zu traden macht wenig Sinn, daher bleibe ich long.

Ausserdem kann jeden Tag die Nachricht von Unternehmens-Teil-Verkäufen o.ä. kommen.

Gruss Loseit

[nort.]

[loseit]

Antwort auf Beitrag Nr.: 21.497.552 von nort. am 09.05.06 22:54:11

Machtkampf um NABI:

http://www.thestreet.com/_yahoo/stocks/pharmaceuticals/10284…

[nort.]

Antwort auf Beitrag Nr.: 21.506.193 von loseit am 10.05.06 15:24:15

Re: Homebrw's opinion
by: goyisha_shyest (53/M/Ft. Worth, Texas) 05/10/06 11:35 pm
Msg: 46736 of 46742

Actually, the "hedgies" are corporate raiders and whores that Merck & Co. set up for the task of raiding NABI for the StaphVAX patent, which is worth tens of billions of dollars, and paying only pennies. If they succeed, the shareholders get screwed out of countless billions. The "hedgies" are fascist pricks is all. What they're aligned with is your your gullible asshole, and they're gonna f*ck it like there's no tomorrow. It's gonna be a close proxy fight. That's why it's so important to vote your proxy in support of the Board of Directors.

WWW.PROXYVOTE.COM

[nkelchen]

Antwort auf Beitrag Nr.: 21.515.504 von nort. am 11.05.06 06:22:00

Wer fliegt heute nach Boca Raton und hat noch ein Ticket über?
Meine Einladung für die morgige HV, ist Gestern eingetroffen!

Ich liebe die Globalisierung...
nk

[nort.]

[nort.]

Nabi is still on track... bei der 7$ Marke wird es spannend...

[nort.]

Antwort auf Beitrag Nr.: 21.612.175 von nort. am 16.05.06 21:05:00

http://phx.corporate-ir.net/phoenix.zhtml?c=100445&p=irol-SE…

http://phx.corporate-ir.net/phoenix.zhtml?c=100445&p=irol-SE…

Insiderkäufe!

Die Story geht weiter

nort

[nkelchen]

Antwort auf Beitrag Nr.: 21.698.065 von nort. am 20.05.06 16:40:22

mag sein, aber die Empfehlungskäufer sind entweder im Minus,
oder schon wieder raus...(so läuft es ja fast immer)
um 5 rum lege ich mir noch ein Päkchen rein...

Gruss
nk

[nkelchen]

Heute Gapschluss bei 5$?!
nk

[nort.]

jetzt sollte das bessere Halbjahr für Bios anstehen...



Also einsteigen und laufen lassen

nort

[nort.]

Kurze Zusammenfassung der letzten Tage:

- Study Designed to Demonstrate Vaccine's Effectiveness in Smoking Cessation; Results Expected Mid-2007 -

ROCKVILLE, Md., May 24 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced that it has initiated a Phase IIB "proof-of-concept" study for NicVAX® (Nicotine Conjugate Vaccine), the company's novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. The study will evaluate the effectiveness of an optimized formulation of the vaccine manufactured at commercial scale in the company's vaccine plant in Florida. The study protocol is based on consultations with U.S. and EU regulators on the design and endpoints for Phase III efficacy studies. Results from this study are expected to be announced in mid-2007. The timing of this study positions the company to be able to initiate Phase III efficacy studies in the second half of 2007.

Nabi Biopharmaceuticals Provides Regulatory Update on Hepatitis B Liver Transplant Programs
Tuesday May 30, 4:51 pm ET
- Next Steps are Advisory Panel Meeting in U.S. and Compiling Stability Data for Reformulated Product in Europe -

The company announced that its Biologic License Application (BLA) for Nabi-HB Intravenous will be reviewed and discussed by the Food and Drug Administration's (FDA) Blood Products Advisory Committee (BPAC) at a meeting scheduled for July 13, 2006 in Gaithersburg, Maryland. The BPAC meeting represents the culmination of lengthy discussions between the FDA and Nabi Biopharmaceuticals concerning the data that might be accepted to support the BLA.


Nabi Biopharmaceuticals Appoints Peter B. Davis, 30-Year Biotechnology Finance Executive, to its Board of Directors
Wednesday May 24, 8:30 am ET
- Davis to Serve on Company's Audit Committee; Expertise in Finance and SEC Reporting Adds Depth and Breadth to Company's Board -

http://biz.yahoo.com/prnews/060524/flw005.html?.v=59


Charttechnisch kurz vor dem Durchbruch...

[nkelchen]

So - Gap geschlossen, bin zu 5,01 mit halber Posi wieder dabei.
Gruss
nk

[nort.]

Antwort auf Beitrag Nr.: 22.010.287 von nkelchen am 08.06.06 16:33:36

gegen das Atmen mit NABI spricht nichts, nur sollte man genügend im Dopet haben, wenn es losgeht...

[loseit]

Antwort auf Beitrag Nr.: 22.010.287 von nkelchen am 08.06.06 16:33:36

Hi nk,

Du scheinst mir ein gutes Timing zu haben.

Hatte auch bei 7 überlegt rauszugehen, aber die Gier war zu gross...

Gib uns armen Unwissenden doch mal'n Tip, wann Zeit für den Ausstieg ist...

Gruss Loseit

[nkelchen]

Antwort auf Beitrag Nr.: 22.020.207 von loseit am 09.06.06 08:59:15

Moin loseit -
ohne etwas Glück, geht bei mir auch nix!
Meine Strategie war ja aber auch eine etwas "andere"
Und die Amis kümmern sich meist sehr rührend um offene Gaps.
Von daher war die 5 schon auffälig.
Wäre mir der Kurs weggerannt, hätte ich halt Pesch gehabt.
Steigenden Kursen laufe ich nicht hinterher, in der Biotech
Schlangengrube schon überhaupt nicht.

Gruss
nk

P.S.
schau dir mal DOVP an -
ich bin zu 50%drin..

[nort.]

Posted: June 9, 2006


Yahoo: Save to My Web

del.icio.us: Save This Page
Smokers Invited To Test Vaccine Against Nicotine Addiction

UCSF's Habit Abatement Clinic is testing a vaccine that enlists help from the immune system to keep nicotine away from the brain. The vaccine is designed to help smokers quit and to limit the urge to start smoking again.
Called NicVax, the investigational vaccine is being developed by Nabi Biopharmaceuticals to prevent and treat nicotine addiction and to help people quit smoking. Normally when a smoker inhales, nicotine is carried by the bloodstream to the brain, where it triggers neuro-receptors to generate positive sensations that can lead to addiction. The vaccine stimulates the immune system to produce antibodies that recognize the small nicotine molecule. Bound to these antibodies, nicotine molecules no longer can cross the blood-brain barrier and enter the brain.

"With little or no nicotine reaching the brain, smoking is less rewarding. That gives the smoker a chance to change the behavioral and social factors that also influence smoking," said Victor Reus, MD, principal investigator for the study at UCSF.

Because immune antibodies remain in the body for some time, Reus said it is hoped that the vaccine also will prevent relapse. When a vaccinated smoker lights up months after quitting, the person should not experience the nicotine-triggered reward that tempts most people back into the habit.

Northern California smokers over 18 are invited to join a national study to determine whether NicVax can help people abstain from smoking and help them avoid relapsing within the next 12 months. Participation is free and requires a one-year commitment to come to San Francisco for injections and follow-up visits. The study also includes five behavioral counseling sessions. Participants will be paid for each visit and given validated parking at the clinic.

For information, interested persons should call the UCSF Habit Abatement Clinic at [phone], visit www.ucsf.edu/nosmoke, or email [e-mail].

UCSF is one of nine centers nationwide to participate in this phase II proof-of-principle clinical trial, which is sponsored by Nabi Biopharmaceuticals of Boca Raton, Florida, and the National Institute on Drug Abuse.

The FDA granted a "fast track" designation for the NicVax vaccine in March, to speed development and review of the drug if trial results are promising.

[nort.]

Antwort auf Beitrag Nr.: 22.053.388 von nort. am 11.06.06 12:48:09

http://www.sciencedaily.com/releases/2006/06/060609170143.ht…

[loseit]

Antwort auf Beitrag Nr.: 22.021.439 von nkelchen am 09.06.06 10:08:56

Hi nk,

danke für den Tip, habe mir die auf die Watchlist gesetzt.
Ist aber Hauptkandidat und einziges Medikament in Phase III.
Laden sehr klein mit 55 MA.

Würde da erstmal abwarten.

Gruss Loseit

[nort.]

Re: ouch
by: mildred_85351 (87/F/Sun City, AZ)
Long-Term Sentiment: Strong Buy 06/23/06 06:00 pm
Msg: 50848 of 50855

Yes, but perfectly within range. I believe that the spurts and drops are perfectly normal considering the current market conditions. Here is a little perspective...

[nort.]

alle schön aufgeladen?

[nort.]

Nabi Teams With Kedrion on Hepatitis Drug
Thursday June 29, 10:28 am ET
Italy's Kedrion Gets License to Commercialize Hepatitis C Drug Candidate Civacir in Europe

BOCA RATON, Fla. (AP) -- Nabi Biopharmaceuticals said Thursday it entered a development agreement with Italian biopharmaceutical company Kedrion S.p.A. to develop and commercialize Civacir, Nabi's hepatitis C treatment candidate, in the U.S. and Europe.

The agreement calls for Kedrion to receive exclusive licensee rights to commercialize Civacir in Europe. Kedrion will give milestone and royalty payments to Nabi and take on the development costs for the product through Phase II trials, Nabi said. Additional financial details of the deal were not disclosed.

The drug candidate, which is moving into mid-stage clinical studies, is aimed at preventing the recurrence of hepatitis C-related liver disease in liver transplant patients who have the disease or receive a liver that is hepatitis C positive.

Nabi shares added 8 cents to $5.69 in morning trading on the Nasdaq.






Italian biotech to fund Nabi drug development
Thursday June 29, 11:08 am ET

Nabi Biophamaceuticals said an Italian biotech company has agreed to develop and commercialize Nabi's drug candidate Civacir.

Kedrion is to pay milestone and royalty payments to Boca Raton-based Nabi (NASDAQ: NABI - News), assume development costs for the drug through at least Phase II clinical trials and exclusively commercialize it in Europe.

Civacir is being developed as the first therapy to prevent the recurrence of hepatitis C-related liver disease for patients with hepatic venous congestion of their transplanted liver.

The companies said they hope to start a Phase II trial for the drug in the United State and Europe the second half of this year.

If successful, they would then plan the definitive Phase III trial.

""This agreement represents a major funding event for Nabi Biopharmaceuticals," said Nabi Chairman, Chief Executive Officer and President Thomas McLain. "This agreement marks a successful achievement of a stated company objective to form strategic partnerships to advance our pipeline programs."

Kedrion President and Managing Director Paolo Marcucci said Civacir would fill a critical and growing void in viable treatment options for liver transplant patients with hepatic venous congestion.

His company has two plants in Italy and specializes in developing plasma-derived drugs such as Civacir.

Dr. Gary L. Davis, medical director of liver transplantation at Baylor Regional Transplant Institute at Texas's Baylor University, said approved therapies for liver transplant patients have minimal efficacy in preventing re-infection of hepatitis C-related diseases, which leads to serious health risks.

"The polyclonal antibody approach of Civacir, either alone or in combination with new antiviral agents that may be developed in the future, is a potential way to neutralize the numerous strains of hepatitis C virus that exist and the dire health consequences that they cause," Davis said.

Published June 29, 2006 by the South Florida Business Journal

[nort.]

http://quotes.barchart.com/texsnap.asp?sym=nabi

[nort.]

Impfstoff gegen Rauchen geht in die zweite Testphase
NicVax hindert Suchtstoff zum Gehirn vorzudringen

http://www.pressetext.at/pte.mc?pte=060706035

[nort.]

Heuschrecken-Alarm!

Hedgefonds setzen das Management von Nabi Biopharmaceuticals unter Druck. Für Anleger könnte das durchaus von Vorteil sein.

Keine drei Monate ist es her, dass DER AKTIONÄR die Aktie von Nabi als spekulativen Top-Tipp vorgestellt hat. Seitdem hat das Papier mit einem Minus von knapp zwei Prozent keine allzu schlechte Figur abgegeben, wenn man bedenkt, dass die Märkte auf breiter Front korrigiert haben. Und die Aussichten auf höhere Kurse sind nach wie vor gut. Zum einen, weil Nabi über vielversprechende Produkte verfügt. Zum anderen, weil sich in der Zwischenzeit mehrere Hedgefonds am Unternehmen beteiligt haben. Deren Manager üben massiv Druck auf die Nabi-Verantwortlichen aus. Ziel: die Steigerung des Shareholder-Value, notfalls auch durch einen Verkauf der Firma.
Mächtig Feuer

Größter Einzelaktionär von Nabi mit einem Anteil von mittlerweile 9,6 Prozent ist der Hedgefonds Knott Partners. Dicht gefolgt von Third Point mit dem berüchtigten Hedgefondsmanager Daniel Loeb an der Spitze. Dieser erhöhte den Anteil an Nabi erst vor wenigen Tagen auf 9,5 Prozent – und macht den Nabi-Chefs ordentlich Feuer. Schon auf der Hauptversammlung im Mai hatte Loeb versucht, den Vorstand zu stürzen. Der Versuch schlug fehl. Vor wenigen Tagen wendete sich Loeb dann in einem Schreiben an die Nabi-Verantwortlichen. Ihnen wirft er Missmanagement und Untätigkeit vor. Nach Loebs Ansicht liegt der faire Wert der Nabi-Aktie bei mindestens zehn Dollar. Und dieser sei am einfachsten zu erreichen, indem das Unternehmen in Teilen oder komplett verkauft werde. Ob es tatsächlich dazu kommt, ist bislang offen. Sicher ist nur, dass die Hedgefonds – vor allem Third Point – angekündigt haben, den Druck auf das Management aufrecht erhalten zu wollen. Die Notwendigkeit, Erfolge zu präsentieren, wächst damit für Nabi-Chef Tom McLain und sein Team.
Ein Engagement wert

Für sehr spekulativ eingestellte Investoren ist die Nabi-Aktie ein Engagement wert. Das Unternehmen verfügt über aussichtsreiche Produktkandidaten, die für einen langfristigen Erfolg stehen. Mittel- bis kurzfristig dürfte sich auch der „Heuschrecken- Alarm“ positiv auf die Kursentwicklung auswirken.



http://www.deraktionaer.de/xist4c/web/Heuschrecken-Alarm-_id…

[nort.]

FDA Panel Advises Approval of Nabi Drug
Thursday July 13, 3:58 pm ET
Nabi Pharmaceuticals Gets FDA Committee Recommendation for Hepatitis B Treatment

BOCA RATON, Fla. (AP) -- Nabi Pharmaceuticals said Thursday a U.S. Food and Drug Administration panel recommended approval of its intravenous hepatitis B treatment candidate.

The drug received a 9 to 2 affirmative vote from the blood products advisory committee to prevent recurrence of hepatitis B in patients who have received liver transplants.

If approved, the company said, the drug would be the only product in use in the United States for the protection of a transplanted liver from hepatitis B, Nabi said.

Shares of Nabi rose 16 cents, or 3.2 percent, to $5.22 in afternoon trading on the Nasdaq. The stock has traded between $3.06 and $15.71 over the past year.

GO NABI GO!

[nort.]

FDA committee favors Nabi hepatitis B drug
Friday July 14, 12:09 pm ET

A Nabi Biopharmaceuticals drug frequently prescribed off-label by doctors may soon get an official approval from federal health regulators.

In a dose of good news for Nabi, which has taken its share of hits lately, a committee of the Food and Drug Administration has voted 9- 2 to recommend approval of the company's intravenous treatment to prevent the recurrence of hepatitis B in patients who have received liver transplants.

ADVERTISEMENT
Nabi currently sells a non-intravenous product to provide protection from infection after accidental exposure to hepatitis B.

This drug, called Nabi-HB, is also used off-label in liver transplant patients at risk for re-infection. Off-label refers to the legal use of a prescription drug to treat a disease for which the drug has not been approved by the FDA.

Executives with Nabi (NASDAQ: NABI - News) -- which is based in Boca Raton, Fla., and has research and development operations in Rockville -- say the positive opinion from the blood products advisory committee bodes well for the drug's future in an intravenous form. The FDA in many instances follows the recommendations of its committees, though it is not obligated to do so.

The Centers for Disease Control and Prevention estimates that there are 8,500 new hepatitis B infections a year in the United States and 5,000 individuals who die annually from the virus or its complications. About 6,000 liver transplants are conducted a year, of which 200 to 250 are due to hepatitis B.

Nabi took a hit late last year when its promising vaccine for staph infections, which many expected to become a blockbuster product, failed in a second round of late-stage testing. Nabi is attempting once more to get this vaccine approved, in addition to other preclinical and clinical products in its pipeline.

Published July 14, 2006 by the Washington Business Journal

[tanteluis]

Wenn der Impfstoff gegen Rauchen alle Phasen besteht und auf den Markt kommt,werden wir ganz andere Kurse sehen!

[loseit]

Antwort auf Beitrag Nr.: 23.158.412 von tanteluis am 28.07.06 21:36:58

Das wird erst gegen 2008/2009 der Fall sein.

Aber der zunehmende News-Flow bei positiven Zwischenergebnissen wird uns schon vorher bis 10 $ katapultieren.

[nort.]

Antwort auf Beitrag Nr.: 23.194.758 von loseit am 29.07.06 07:46:50

sehe ich genauso loseit

[nort.]

was ist den da los?

AH + 14,68% ??

[loseit]

Antwort auf Beitrag Nr.: 23.250.180 von nort. am 31.07.06 07:10:46

Hat nix zu bedeuten.
Kurs wieder normal.

Glaube trotzdem, dass wir heute über 5.00 schliessen.

Gruss Loseit

[nort.]

[herrhotzenplotz]

melde mich mal als sonst "nur- leser"

nichts mehr los hier,...hm ?!

sollte das teil beim nächsten versuch nicht durch die 6$
gehen, fliegt sie bei mir zumindest raus... kk 2,7€
meinungen ?

grüße an die investierten

[herrhotzenplotz]

na also...
geht doch !!
lg

[doc57]

Nabi hat m.E. einen sehr erfreulichen Deal mit FMC abgeschlossen. Sollte dem Wert neuen Schub geben. Scheinen in USA bereits einege bemerkt zu haben. Good luck

[herrhotzenplotz]

right...

auf die zeeeehn !!

[doc57]

Antwort auf Beitrag Nr.: 25.420.203 von herrhotzenplotz am 15.11.06 18:40:31

Sehe ich das richtig, dass der Deal mit FMC der Firma Nabi ca. 1,5 bis 2 $/ Aktie an Einmaleinnahmen bringt. Habe gelesen, dass es sich um ein Volumen von ca. 150Mio handeln soll, genannt werden 65 Mio $ sofort und weitere Zahlungen in den nächsten Jahren. Hat jemand dazu eine Meinung? Wenn das stimmt, könnte der Kurs noch einen schönen Schub bekommen.

[doc57]

Antwort auf Beitrag Nr.: 25.526.427 von doc57 am 19.11.06 14:35:58

Auf ariva wird die aktuelle MK mit 327 Mio angegeben. Das würde doch wohl bedeuten, dass Nabi von FMC fast die Hälfte seiner aktuellen Bewertung erhielte. Wenn die Zahlen stimmen, ergäbe das ein tolles Kurspotential.

[herrhotzenplotz]

Antwort auf Beitrag Nr.: 25.526.491 von doc57 am 19.11.06 14:42:20

hi,

find die meldung auch nicht schlecht...
schade daß kaum reaktion an den märkten kam
65 mio gibt´s jedenfalls sofort und den rest (bis zu 85mio) gibt´s
gegebenenfalls durch milestone- bzw dann lizenzzahlungen;
also alles keine festen größen

die verhaltene reaktion führe ich darauf zurück, daß nabi immer noch
viel geld verbrennt, es somit auch dringend nötig hat und ansonsten mit "guten" meldungen ziemlich geizt...

den chart finde ich jedenfalls interessant
die richtung stimmt erstmal und demnächst (auch ohne news!) sollten die 8,5 mit schwung durchstoßen werden... wenn sich die 7 jetzt erstmal stabilisieren können;
ziel wären dann für mich die 10

viel glück

[herrhotzenplotz]

Antwort auf Beitrag Nr.: 25.671.159 von herrhotzenplotz am 24.11.06 19:06:10

ok...
alles in $

[herrhotzenplotz]

Antwort auf Beitrag Nr.: 25.671.159 von herrhotzenplotz am 24.11.06 19:06:10

tja mein lieber

...so kann man sich täuschen
dauert anscheinend alles etwas länger


ne danke... machs gut nabi...:O
allen anderen viel glück weiterhin
gruß

[nort.]

[nort.]

[johnnt]

Antwort auf Beitrag Nr.: 30.482.991 von nort. am 04.07.07 12:31:34

hey, was ist denn da plötzlich los?
weiss da jemand mehr?

[Freestyler2001]

heute 14% Einbruch...weiß jemand was da los ist? Konnte auf der HP nichts finden.

[johnnt]

Antwort auf Beitrag Nr.: 31.072.236 von Freestyler2001 am 07.08.07 22:56:40

Nabi Biopharm 2nd Quarter Loss Narrows; Revenue Up 2.4%
By Andrew Edwards
Last Update: 4:10 PM ET Aug 1, 2007

Nabi Biopharmaceuticals's (NABI :
nabi biopharmaceuticals com
News , chart , profile , more
Last: 3.32-0.56-14.44%
4:03am 08/08/2007
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
NABI3.32, -0.56, -14.4% ) second-quarter loss narrowed to $4.78 million, or 8 cents a share, from $14.8 million, or 24 cents a share, a year earlier, as revenue rose 2.4%. The Boca Raton, Fla., company's revenue to $20.9 million from $20.4 million in the year-ago period. On average, analysts expected a per-share loss of 18 cents on revenue of $22.70 million, according to a poll by Thomson Financial. Nabi's shares closed Wednesday up 14 cents, or 3.3%, at $4.40.

[Freestyler2001]

habe mal zugeschlagen und mir ein paar Stk. ins Depot gelegt ist ja lächerlich was da abläuft. Siehe da schon sind die ersten 8% eingefahren Langfristig kann man noch einiges von Nabi erwarten.

@ johnnt thx fürs Posting!